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ABSTRACT 
 
The ease of genome sequencing over the past decade has greatly facilitated the 
identification of genetic mutations causing a large number of human diseases. However, 
in the vast majority of cases, how these mutations lead to disease remains an enigma. 
Targeted genome engineering via the RNA-guided CRISPR/Cas9 nuclease system offers 
the possibility of faithfully mimicking molecular mutations in their endogenous context 
to study underlying mechanisms. In this study, I explored the question of whether 
genome editing is an effective approach to model a novel genetic disease. Recently, our 
laboratory has identified two patients with a distinct form of congenital dyserythropoietic 
anemia, characterized by erythroid and megakaryocytic dyplasia and mild elevations in 
fetal hemoglobin levels. Curiously, the coding sequence of DNA from the patients was 
unremarkable but further analysis revealed a common hemizygous point mutation in the 
last intron of GATA1 (chrX: 48,652,176 C>T in hg19). This gene encodes the 
hematopoietic master regulatory transcription factor GATA1 essential for the 
differentiation of erythrocytes and megkaryocytes. Genetic mapping and segregation 
within the families provided strong evidence to support a causal relationship between the 
mutation and disease. To model the disease in a tractable system and further understand 
the underlying basis by which the mutation results in disordered blood production, I 
performed genome editing with CRISPR/Cas9 in a human erythroid cell line to recreate 
this intronic GATA1 mutation. I designed and cloned nine distinct single guide RNAs 
(sgRNAs) and identified one that cleaved the target locus in an efficient manner. Using 
this sgRNA, I showed that an increased mass ratio of exogenous repair template to 
sgRNA to Cas9 dramatically improved GATA1 editing efficiency and diversity. The rate 
of genomic perturbation increased from 20% to 80% and incorporation of the intronic 
mutation via homology directed repair occurred at 3.8%. Using three computational 
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methods, I characterized all allele-specific editing events in 133 isogenic cell lines and 
mapped them by genomic position relative to the Cas9 cleavage site. I found that most 
GATA1 changes occurred within 15 bp of the Cas9 cleavage site and the editing 
frequency is higher upstream than downstream at each position equidistant from the 
predicted double-strand breaks. Consistent with this observation, most GATA1 edits 
occurred within the intron and those that altered the downstream canonical splice 
acceptor site and exon were exclusively heterozygous. These findings suggest that the 
human erythroid cell line disfavors alteration of sequences essential for proper function 
of GATA1, via splicing regulation or protein coding. Notably, the desired homozygous 
C>T mutations co-occurred with additional modifications such as deletion of an 
alternative splice acceptor site and the protospacer adjacent motif (PAM) required for 
Cas9 binding. It is possible that concurrent deletion of the alternative splice acceptor site 
rescues the splicing defect from the mutation and genome editing recurred until PAM 
was rendered unrecognizable. Following these experiments, my colleagues demonstrated 
that the C>T mutation results in activation of the alternative splice acceptor site and a 
partial intron retention event using transient expression of a minigene. The observed 
splicing alteration was confirmed in patient samples and further experiments showed that 
the resultant GATA1 protein is inactive. While many recent proof-of-principle studies 
have described successful application of genome editing to generate models of common 
diseases with well-established genetic alterations, no study has yet modeled a novel 
disease with a novel mutation and provided insight into disease pathophysiology. I 
conclude with important limitations of using CRISPR/Cas9 for disease modeling and 
discuss possible solutions and efficient alternatives. These lessons have broad 
implications for future applications of genome editing and classical approaches to study 
disease in an effort to generate functionally and clinically relevant knowledge. 
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CHAPTER 1. INTRODUCTION 
 
1.1 Next-generation sequencing heralds an explosion of data 
Since the discovery of the structure of DNA, technological advances in 
sequencing have opened greater and greater territory in the genome for the study of 
human health and disease. Early studies characterized single genes associated with highly 
penetrant diseases such as cystic fibrosis, Huntington’s disease, and certain types of 
cancer. Many innovations and collaborations then supported the Human Genome Project, 
the completion of which in 2003 engendered more complex biological questions and 
revealed a need for more accessible and robust sequencing methods. Since the mid-
2000s, high-throughput sequencing platforms have decreased the cost of human genome 
sequencing by 50,000-fold and increased capacity by a factor 100-1,000 (Goodwin et al., 
2016). These breakthroughs ushered an era of next-generation sequencing and shifted the 
paradigm to address biological questions on a genome-wide scale. 
Next-generation sequencing decodes genomes through a variety of creative 
approaches. Most widely used are short-read approaches, in which DNA fragments 
ligated to adapters are clonally amplified on a solid surface and their compositions are 
detected via a secondary signal, such a fluorophore conjugated to a single nucleotide or a 
degenerate oligonucleotide or a change in pH associated incorporation of a defined base 
(Ju et al., 2006; Rothberg et al., 2011). A platform can simultaneously collect information 
from millions of reaction centers, each with its own clonal DNA template, allowing 
millions of DNA molecules to be sequenced in parallel. While short-read approaches 
maximize the number of bases sequenced in the least amount of time, long-read 
approaches aim to identify longer pieces of contiguous DNA to resolve structurally 
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complex regions, such as highly repetitive elements and copy number alterations. Instead 
of clonal amplification, a single DNA molecule progresses through a polymerase fixed to 
the transparent bottom of a picoliter well and its composition is detected through 
incorporation of fluorophore-bound nucleotides (Levene et al., 2003; Eid et al., 2009). 
Alternatively, a system of barcoding can associate fragments sequenced from short-read 
approaches to create synthetic long reads (McCoy et al., 2014). While whole genome 
sequencing provides the most comprehensive view, whole exome and targeted 
sequencing can save time and cost by limiting the genomic material to all coding exons 
or a custom panel of targeted regions.   
The advent of next-generation sequencing has enabled interrogation of nearly 
every base in the genome. Unlike genome-wide association studies (GWAS), which 
examine common variants on microarrays, sequencing enables discovery of rare variants 
with large effects that contribute not only to rare inherited disorders but also common 
complex diseases not explained by common variants with low to moderate effects 
(Schork et al., 2009). For example, exome sequencing of two family members with 
combined hypolipidemia, a rare inherited disorder, identified two distinct nonsense 
mutations in ANGPTL3, which encodes angiopoietin-like 3 protein reported to inhibit 
lipoprotein lipase and endothelial lipase (Musunuru et al., 2010). Exome sequencing of 
an Italian family with autosomal dominant amyotrophic lateral sclerosis, another rare 
inherited disorder, showed a missense mutation in VCP, which encodes valosin-
containing protein essential for maturation of ubiquitin-containing autophagosomes 
(Johnson et al., 2010). As for common complex diseases, exome sequencing of a three-
generation family with multiple individuals affected by pulmonary arterial hypertension 
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revealed a frameshift mutation in CAV1, which encodes caveolin-1 abundant in the 
endothelium and other cells of the lung (Austin et al., 2012). Exome sequencing of 
multiplex families with schizophrenia identified rare coding variants in several genes 
associated with the N-methyl-D-aspartate (NMDA) receptor, implicating glutamate 
signaling in the pathogenesis of schizophrenia (Timms et al., 2013). These studies are 
only a few examples of how rare mutations present fertile ground for further investigation 
of both Mendelian and complex diseases.  
Fueled by next-generation sequencing, the number of inherited phenotypes for 
which the genetic basis is known has nearly doubled from 2007 to 2013 according to the 
Online Mendelian Inheritance in Man (OMIM) database (Koboldt et al., 2013). Likewise, 
the number of known variants in the human genome has risen dramatically over the past 
decade as seen in Single Nucleotide Polymorphism database (dbSNP). A comparison of 
dbSNP 135 from October 2011 with dbSNP 137 from June 2012 reveals that most of the 
recent growth came from variants that are rare (global minor allele frequency < 0.01) or 
extremely rare (global minor allele frequency < 0.001) in human populations. For many 
disorders, discovery of the genetic basis has clearly outpaced an understanding of the 
molecular mechanisms of disease. As sequencing technologies continue to improve and 
new data continue to accumulate, elucidating the precise relationship between genotype 
and phenotype and generating functionally and clinically relevant knowledge have 
become the primary challenge. 
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1.2 Genome editing holds promise in human disease modeling 
 Classical approaches to establish gene function include homologous 
recombination for targeted gene inactivation and RNA inference for targeted gene 
expression knockdown (Smithies et al., 1985; Thomas and Capecci 1987; McManus and 
Sharp 2002). Though powerful, both methods have important drawbacks. Homologous 
recombination is difficult because engineered constructs insert into chromosomal target 
sites at low efficiency and selection of correctly modified gene is time-consuming and 
labor-intensive. The newer RNA inference technology is a more efficient alternative to 
homologous recombination but gene expression knockdown is often transient and 
incomplete with possible confounding by off-target effects (Qiu et al., 2015).  
During the last decade, genome editing, also known as genome engineering, has 
emerged as a new approach to study genetic alterations. Methods are based on the use of 
programmable nucleases to induce double-strand breaks (DSBs) at target DNA sites, 
which stimulate cellular repair mechanisms such as the efficient but error-prone non-
homologous end joining (NHEJ) pathway and the high-fidelity but less efficient 
homology directed repair (HDR) pathway. NHEJ often results in insertions or deletions 
(indels) at the target site and can knockout gene function via frameshift mutations 
(Figure 1B). HDR is more precise and can incorporate specific mutations, insertions, or 
deletions via a donor template bearing the desired change and locus-specific homology 
arms (Figure 1C). Genome editing enables manipulation of virtually any sequence in the 
genome, from single-nucleotide changes to larger insertions and deletions. 
The repertoire of tools to induce site-specific DSBs includes zinc finger nucleases 
(ZFNs), transcription activator-like effector nucleases (TALENs), and clustered 
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regulatory interspaced short palindromic repeat (CRISPR)/Cas-based RNA-guided DNA 
endonucleases (Gaj et al., 2013). ZFNs consist of a custom array of site-specific DNA 
binding domains adapted from zinc finger transcription factors, each of which binds 3-4 
bp, fused to the nuclease domain of the bacterial FokI restriction enzyme. Similarly, 
TALENs consist of a tandem array of DNA binding domains adapted from TAL repeats, 
each of which binds 1 bp, fused to the nuclease domain of FokI. Unlike ZFNs and 
TALENs, CRISPR/Cas systems use a combination of guide RNA and Cas nuclease to 
detect and cleave the target sequence (Figure 1A). In bacteria, CRISPR provides 
acquired immunity by accumulating short segments of foreign DNA, termed 
“protospacers,” from plasmids and phage genomes (Wiedenheft et al., 2012). These 
sequences are transcribed and processed into short CRISPR RNAs (crRNAs) that 
recognize specific target DNA and anneal to trans-activating crRNAs (tracrRNAs) that 
bind Cas nuclease to direct target cleavage. In 2013, four groups demonstrated that 
expression of Streptococcus pyogenes Cas9 and a single guide RNA (sgRNA) fusing 
crRNA-tracrRNA in mammalian cells induced targeted DSBs (Cong et al., 2013; Mali et 
al., 2013; Jinek et al., 2013; Cho et al., 2013). The target sites in the mammalian genomes 
contain a 20 bp sequence that match the protospacer sequence of the guide RNA and an 
adjacent NGG, or protospacer adjacent motif (PAM) recognized and required by Cas9. 
The main advantage of CRISPR, compared to ZFNs and TALENs, is the ease with which 
sgRNAs can be synthesized for targeted modification of different sequences. 
Genome editing can replicate or correct mutations in their endogenous context 
and holds enormous promise in disease modeling. Barth syndrome, for example, is an X-
linked cardiac and skeletal mitochondrial myopathy caused by mutations in TAZ, which 
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encodes a protein called tafazzin responsible for normal acylation of cardiolipin, a major 
phospholipid of the mitochondrial inner membrane. Wang et al. (2014) generated patient-
derived cardiomyocytes via reprogramming of skin fibroblasts into induced pluripotent 
stem cells (iPSCs) and found that the cells assembled sparse and irregular sarcomeres and 
engineered tissues contracted weakly. They mutated TAZ in control iPSCs using 
CRISPR/Cas9, induced cardiomyocyte differentiation, and demonstrated, elegantly, that 
the mutations were necessary and sufficient to replicate the phenotypes observed in 
patient-derived cardiomyocytes. In another study, Pashos et al. (2017) discovered DNA 
variants in genomic loci associated with regulation of blood lipid traits such as total 
cholesterol, LDL, HDL, and cholesterol and recapitulated those SNPs via CRISPR/Cas9 
in human pluripotent stem cells for functional validation. Other studies demonstrated 
correction of disease-causing genes using CRISPR/Cas9, such as CFTR in intestinal stem 
cell organoids derived from cystic fibrosis patients (Schwank et al., 2013), DMD in 
iPSCs derived from patients with Duchenne muscular dystrophy (Li et al., 2014), and 
HBB in iPSCs derived from patients with !-thalassemia (Xie et al., 2014). These studies 
show that genome editing is a powerful approach to model disease and has potential to 
provide great insight into pathophysiology. 
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Figure 1. RNA-guided CRISPR-Cas9 enables targeted genome editing
(A) Guide RNA is a short synthetic RNA composed of a scaffold sequence (tracrRNA) that binds to Cas9 
nuclease and a 20 nucleotide spacer (crRNA) that provides genomic targeting specificity. The seed 
sequence refers to 8-10 bases at the 3’ end of the spacer, where mismatches are not well tolerated. The 
ideal targeting sequence is unique in the genome and adjacent to a protospacer adjacent motif (PAM), 5’-
NGG-3’ when S. pyogenes Cas9 is used. Once Cas9 binds to a single guide RNA (sgRNA), it undergoes a 
conformational change that permits DNA binding. It undergoes a second conformation change upon binding 
of the Cas9-sgRNA ribonucleoprotein to target DNA that positions the nuclease domains for DNA cleavage 
at ~3-4 nucleotides upstream of PAM. (B) The resulting double-strand breaks (DSB) can be repaired by the 
efficient but error-prone non-homologous end joining (NHEJ) pathway. This mechanism often results in 
small nucleotide insertions or deletions (indels) at the DSB site. (C) Alternatively, the resulting DSB can be 
repaired by the high-fidelity but less efficient homology directed repair (HDR) pathway. HDR can be used to 
generate specific nucleotide changes using a DNA repair template containing the desired mutation. Single-
stranded donor oligonucleotides are commonly used for short modifications.
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1.3 Patients with an unusual anemia share an intronic mutation in GATA1  
Two unrelated boys in Germany and the United Kingdom presented with a 
peculiar form of dyserythropoietic anemia involving persistence of fetal hemoglobin. The 
patients required transfusions in early infancy but subsequently evolved a milder anemia 
that worsened in the setting of infections. Common anemias fall into the three broad 
categories of red cell underproduction, red cell destruction, and excessive blood loss. 
While some clinical features of the patients indicate hemolysis, others such as dysplastic 
erythropoiesis on bone marrow biopsy, persistent macrocytosis in the absence of 
nutritional deficiencies (MCV ~100 fl), elevated fetal hemoglobin post-infancy (~20-
23%), and thrombocytopenia with defective platelet function (decreased expression of P-
selectin/CD62 and LAMP-3/CD63) suggest atypical hematopoiesis of an intrinsic nature. 
Extensive workup excluded membranopathies, hemoglobinopathies, and enzymopathies. 
Curiously, whole exome sequencing was unremarkable but an expanded search including 
all rare variants in known red blood cell disorder genes revealed a hemizygous point 
mutation in the fifth intron of GATA1 (chrX: 48,652,176 C>T in hg19) (Figure 2). This 
gene encodes the hematopoietic master regulatory transcription factor GATA-binding 
protein-1 (GATA1). The mutation replaces cytosine with thymine 24 nucleotides 
upstream of the canonical splice acceptor site at 3’ end of the intron. The mothers of the 
two boys are carriers for this mutation on the X chromosome and population studies 
confirmed its absence from thousands of healthy individuals. 
 
 
 
AB
Exon 
Exon 4
Exon 5
Exon 6
GATA1 Gene
Mutation: 
ChrX: 48,652,176 C>T 
5’...ATTGTCAGTAAACGGGCAGGTACTCAGTGCACCAACTGCCAGACGACCACCACGACACTG
TGGCGGAGAAATGCCAGTGGGGATCCCGTGTGCAATGCCTGCGGCCTCTACTACAAGCTACAC
CAGGTGACGCCCTGCCCCTTGGAGCCACCCCTCTGCTTTCCCTGTCTTCATGCCACACTGCCC
CCCACTCTGTTCCTGTTCTACCTCTCTCTTCCCCCACAACCCTCTTTCCTCTTTCCCCTTTCCCTC
CTTCCTCCCCCTTCCCCCATCTCTTCTACTTTCCCCCTTCCTCCATCTCTTCTACTTTCCCCCTTC
TCTGTTATTACCCTCCCTCCTTCCTTCTCCATTCCCTCCTCCTCCGCCCTCCTCCTTCCTCTCCTC
TCCCCCACCTCCAGGCATCAGCTAATGTCCAACCCCCTGCCCTAGACCTTGGGCAGCTCCTATC
AGCCTTGGAGGCTTTCCTAAGCTCAGGGCCTCACAGCCTCAGGATTCCTTGGACAATCTCAGC
ACCCAAAAATTATCTTACCCTGAAAGAAGTGGGGTAGAGAGGGTGTCCCTGGTTGACACAGAG
AGGCAAAGGTCTGGAGTTGGGGACACCCGCAGCCTCCTTTTTGGCAGGTGAACCGGCCACT
GACCATGCGGAAGGATGGTATTCAGACTCGAAACCGCAAGGCATCTGGAAAAGGGAAAAAGA
AACGGGGCTCCAGTCTGGGAGGCACAGGAGCAGCCGAAGGACCAGCTGGTGGCTTTATGGTG
GTGGCTGGGGGCAGCGGTAGCGGGAATTGTGGGGAGGTGGCTTCAGGCCTGACACTGGGCC
CCCCAGGTACTGCCCATCTCTACCAAGGCCTGGGCCCTGTGGTGCTGTCAGGGCCT...3’
Figure 2. Two unrelated patients with a distinct form of dyserythroplastic anemia have a single 
nucleotide mutation in the last intron of GATA1
(A) The human GATA1 gene is located on chromosome X and spans 7751 bp. In healthy individuals, 
alternative splicing produces an mRNA containing exons 1-6 that specifies the full-length GATA1 and a 
second mRNA with skipping of exon 2 that specifies the truncated GATA1s lacking the N-terminal 
transactivation domain. Exon 1 (white box) is untranslated and consists of IT and IE components that 
regulate expression in Sertoli cells and hematopoietic cells, respectively. Two unrelated patients with a 
distinction presentation of dyserythropietic anemia were noted to have a unique mutation in intron 5 of 
GATA1 (ChrX:48,652,176 C>T) after whole exome sequencing was found unrevealing. (B) The expansion 
shows the sequence of exon 5 (gray), intron 5 (black), and exon 6 (gray). The identified mutation (large red 
C) is located 24 nucleotides upstream of the canonical splice acceptor site (blue). Blue “AG”, canonical 
splice acceptor site. Purple “AG,” potential alternative splice acceptor site. Blue highlight, potential intron 
splicing enhancer. Yellow highlight, potential polyprimidine tract bound by U2-auxiliary factors. 
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1.4 GATA1 plays an important role in development and disease 
Since the first description of GATA1 in 1988, as a protein bound to the 3’ 
enhancer of the human !-globin gene, and its landmark cloning in 1989, studies have 
illuminated many aspects of its critical function in hematopoiesis (Wall et al., 1988; Tsai 
et al., 1989). GATA1 plays an essential role in erythroid development. Mouse embryos 
lacking the transcription factor die from severe anemia between embryonic day 10.5 and 
11.5 (Fujiwara et al., 1996). Embryonic stem cells deficient in GATA1 contribute to all 
tissues in chimeric mice but not red blood cells (Pevny et al., 1991). Erythroid maturation 
arrests at the proerythroblast stage and precursors die by apoptosis (Pevny et al., 1995; 
Weiss and Orkin, 1995). In accordance with these observations, GATA1 promotes the 
survival of erythroid progenitors by activating genes that encode the erythropoietin 
receptor and the anti-apoptotic protein BCL-XL (Zon et al., 1991; Gregory et al., 1999). It 
activates genes important for red cell function, such as those encoding "- and !-globins 
and heme biosynthesis enzymes (Evans et al., 1988; Orkin, 1992). Concurrently, it 
represses genes associated with immature, proliferative state, including several core 
regulators of cell cycle progression (Rylski et al., 2003). In addition, GATA1 is 
expressed in megakaryocytes, eosinophils, mast cells, and Sertoli cells of the testis and 
play essential roles in maturation of megakaryocytes and eosinophils (Ferreira et al., 
2005) (Figure 3). Much of our knowledge about GATA1 is derived from mouse models, 
grounded in the nearly identical morphology of human and mouse erythroid 
differentiation. Recent studies, however, note a global divergence in interspecies 
expression profiles and transcription factor occupancy (Ulirsch et al., 2014). Conserved 
regulatory regions correspond to a minority of genes essential for the erythroid cell state 
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(e.g. !-globin, heme biosynthesis enzymes, red cell membrane and surface proteins), as 
they are likely under strong evolutionary constraint. 
The structure of GATA1 corresponds elegantly to its function. The protein has a 
C-terminal zinc finger that binds to the GATA consensus sequence (A/T)GATA(A/G), an 
N-terminal zinc finger that stabilizes DNA interactions, and an N-terminal activation 
domain necessary for transcriptional activation activity at least in exogenous assays 
(Ferreira et al., 2005). GATA1 can self-associate and interact with a variety of proteins, 
including cofactors, transcription factors, chromatin-remodeling complexes, and cell 
cycle regulators. Of particular significance is Friend of GATA1 (FOG1), which binds to 
the N-terminal zinc finger of GATA1 and synergizes with the transcription factor in gene 
activation and repression (Fox et al., 1998; Tsang et al., 1997). FOG1 is critical to 
GATA1 function as mutations that disrupt their interaction block erythropoiesis and 
compensatory mutations that restore their interaction rescue the phenotype (Crispino et 
al., 1999). TAL1 is another important cofactor that interacts via LMO2 with the N-
terminal zinc finger of GATA1 (Wadman et al., 1997). Unlike FOG1, however, TAL1 
and LMO2 cooperate with GATA1 in gene activation but not repression (Tripic et al., 
2009; Campbell et al., 2013). 
The vast majority of disease-causing mutations perturb the N-terminal domains of 
GATA1. Missense mutations in the N-terminal zinc finger produce a spectrum of red 
blood cell and platelet disorders. Not surprisingly, those that severely diminish FOG1-
GATA1 interactions (V205M, G208R, D218Y) cause profound anemia and 
thrombocytopenia and early mortality, whereas those that slightly diminish FOG1-
GATA1 interactions (G208S, D218G) or disrupt GATA1-LMO2 interactions (R216Q, 
  12 
R216W) result in moderate disease (Campbell et al., 2013). Healthy individuals express 
both full-length GATA1 as well as a truncated form (GATA1s) lacking the N-terminal 
transactivation domain (Wechsler et al., 2002). Exclusive expression of GATA1s due to 
loss of the first methionine, splicing errors, and premature termination codon underlies 
transient abnormal myelopoiesis and myeloid leukemia in children with Down syndrome 
(Kanezaki et al., 2010). Furthermore, rare mutations that altered the exon 2 donor splice 
site and the first translation initiation codon of GATA1 led to the discovery that reduced 
translation of the full-length protein serves as the link between ribosomal protein 
haploinsufficiency in Diamond-Blackfan anemia and selective aplasia of the erythroid 
lineage (Sankaran et al., 2012; Ludwig et al., 2014). With a paucity of mutations 
affecting the C-terminal domain of GATA1, likely reflecting their lethality, the mutation 
in the last intron may open new understanding of the developmental control and function 
of this hematopoietic master regulator. 
 
 
 
 
 
 
 
 
 
 
Figure 3. The transcription factor GATA1 plays an essential role in hematopoiesis
Hematopoietic stem cells in the bone marrow can self-renew to maintain their multipotency or give rise to to 
early progenitors restricted to myeloid or lymphoid differentiation. Common myeloid progenitors mature into 
erythrocytes, megakaryocytes, granulocytes, and monocytes. Common lymphoid progenitors mature into B-
cells, T-cells, and natural killer cells of the immune system. GATA1 plays an essential role in erythroid 
development. It activates genes important for red cell function, such as those encoding !- and "-globins 
and heme biosynthesis enzymes, and represses genes associated  with immature, proliferative state, 
including several core regulators of cell cycle progression. In addition to erythroid cells, GATA1 is expressed 
in megakaryocytes, eosinophils, mast cells, and Sertoli cells of the testis and plays essential roles in the 
maturation of megakaryocytes and eosinophils. 
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1.5 Pre-mRNA splicing is a highly regulated process 
The mechanism of the intronic mutation is enigmatic and likely involves the 
modulation of splicing. The distribution of non-coding introns among coding exons was 
first recognized via the expression of adenovirus (Berget et al., 1997; Chow et al., 1977). 
Now, it is known that human genes express pre-mRNAs containing eight exons on 
average (Wang and Cooper, 2007). While exons are typically 50-250 base pairs in length, 
introns are typically hundreds to thousands of base pairs and account for >90% of the 
transcription unit on average (Lander et al., 2001; Wang and Burge, 2008). Most human 
genes undergo alternative splicing or joining of exons that controls gene expression and 
generates proteomic diversity. GATA1, for example, contains two alternative untranslated 
first exons, IT and IE, and five translated exons, II to VI (Ito et al., 1993; Tsai et al., 
1991). In humans, alternative splicing produces an mRNA containing exons 
I/II/III/IV/V/VI that specifies the full-length GATA1 and a second mRNA containing 
exons I/III/IV/V/VI that specifies the truncated GATA1s (Halsey et al., 2010). The 
untranslated exons IT and IE regulate expression in Sertoli cells and hematopoietic cells, 
respectively (Ito et al., 1993). The long and short forms show similar DNA binding but 
different transactivation potential, as exon II encodes the first 83 amino acids for the N-
terminal transactivation domain (Martin and Orkin, 1990). Even more dramatic is the 
alternative splicing of BCL-X, which produces a smaller mRNA for the pro-apoptotic 
protein BCL-XS and a larger mRNA for the anti-apoptotic protein BCL-XL, the latter of 
which increases in late erythroid maturation (Motoyama et al., 1995). Splicing is tightly 
regulated in a developmental stage- and tissue-specific manner. Global analysis during 
erythroid differentiation show significant changes in alternative splicing, affecting a wide 
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range of functions from transmembrane receptor activity and chromatin modification to 
RNA processing and DNA packaging (Cheng et al., 2014). As an error of even a single 
nucleotide can disrupt the open reading frame and abolish the function of a protein, 
splicing must occur with extraordinary precision. 
Core splicing signals are present in every intron and play instructive roles in 
splicing reactions. They include the 5’ and 3’ splice sites at the intron-exon junctions and 
the branch point sequence approximately 21-34 nucleotides upstream of the 3’ end of an 
intron (Wang and Burge, 2008; Gao et al., 2008). The majority of 5’ and 3’ splice sites 
contain the consensus sequences GURAGU and YAG, respectively, where R is a purine 
(A or G) and Y is a pyrimidine (C or U) (Singh and Cooper, 2012). The first and last two 
nucleotides of an intron, GU and AG, are almost invariant, whereas other nucleotides are 
more variable (Wang and Burge, 2008). The human branch point sequence contains a 
well-conserved adenosine and uridine but other positions are highly degenerative (Gao et 
al., 2008). Pre-mRNA splicing occurs via two sequential transesterification reactions, 
where the 2’-hydroxyl group of the branch point adenosine performs a nucleophilic attack 
on the first nucleotide of the 5’ splice site and then the 3’-hydroxyl group of the upstream 
exon performs a second nucleophilic attack on the last nucleotide at the 3’ splice site, 
joining the exons and releasing the intron lariat (Fica et al., 2013). The spliceosome 
mediates splice site recognition and catalysis of the reactions. It is composed five small 
nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 in the major assembly, 
and approximately 150 proteins (Singh and Cooper, 2012). Initially, U1 binds to the 5’ 
splice site, U2 binds to the branch point sequence, and U2-auxiliary factors bind to the 3’ 
splice site and upstream polypyrimidine tract. U4, U5, and U6 then join the assembly to 
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remodel the complex. U1 and U4 subsequently exit and U6 catalyzes the 
transesterification reactions (Fica et al., 2013). The stepwise assembly of snRNPs and 
interaction of numerous proteins contribute to the precision of splicing. 
Nevertheless, core splicing signals contain only about half of the information 
required for accurate splice site recognition (Lim and Burge, 2001). Many cis-regulatory 
elements are thought to reside in exons and introns and function as splicing enhancers 
and silencers (Matlin et al., 2005; Wang and Burge, 2008). By recruiting trans-acting 
factors, they promote or inhibit splice site recognition or spliceosome assembly in an 
additive manner. Exonic splicing enhancers (ESEs) and silencers (ESSs) regulate 
inclusion of the exon in which they occupy. Most ESEs recruit SR proteins that facilitate 
spliceosome assembly (Graveley and Maniatis, 1998). ESSs often recruit heterogeneous 
nuclear ribonucleoproteins (hnRNPs) that can displace snRNP binding, block interactions 
between snRNPs, or loop out exons (Zhu et al., 2001; Nasim et al., 2002; Sharma et al., 
2005). Intronic splicing enhancers (ISEs) and silencers (ISSs) regulate inclusion of 
adjacent exons. They recruit a variety of trans-acting factors including hnRNPs and 
tissue-specific proteins (Hui et al., 2005; Nakahata and Kawamoto, 2005). While exonic 
elements are diverse in sequence and large-scale computational and experimental studies 
have contributed to predictive algorithms, intronic elements are less well characterized 
and many remain unknown (Chasin, 2007). Reported intronic motifs include G triplet 
(GGG) and G runs (Gn; n # 3), which are common in GC-rich introns and function as 
ISEs, and CA repeats, which can function as ISE or ISS depending on their distance to 
the upstream exon (McCullough and Berget, 1997; Hui et al., 2005). Importantly, these 
cis-regulatory elements are context-dependent and often have variable effects depending 
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on their relative positions in the pre-mRNA and gene-specific local secondary structure 
(Wang and Burge, 2008). Splicing is also intimately linked to the entire process of 
mRNA transcription, processing, and transport (Hieronymus and Silver, 2004). 
 
1.6 Splicing alterations occur in many diseases  
Mutations that disrupt splicing constitute a major cause of disease (Singh and 
Cooper, 2012). Many act through a single gene by perturbing its splicing code, while 
some act through multiple genes by perturbing the splicing machinery (Dolatshad et al., 
2015). The former are cis-acting mutations and include those in the core splicing signals 
and the regulatory elements that function as splicing enhancers and silencers. The latter 
are trans-acting mutations and include those in the spliceosomal factors and the auxiliary 
factors that promote or suppress recognition of nearby splice sites. 
Cis-acting mutations cause disease through four general mechanisms: 1) 
constitutive exon skipping or intron retention, 2) activation of cryptic splice sites or 
pseudoexons, 3) altered inclusion:exclusion ratio of alternative exons, or 4) aberrant 
splicing mediated by transposable elements (Singh and Cooper, 2012). Mutations in the 
first category reduce the recognition of 5’ or 3’ splice site by modifying the consensus 
sequence of core signals or disrupting the exonic or intronic enhancer elements. Exon 
skipping is most common but intron retention can occur. These mutations produce an 
unnatural mRNA that translates into a nonfunctional protein or introduce a premature 
termination codon (PTC) that targets the mRNA for degradation by nonsense mediated 
decay (NMD). Examples include mutations in transient abnormal myelopoiesis and 
myeloid leukemia of Down syndrome that introduce PTCs after the second translation 
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initiation codon of GATA1 at codon 84, which result in low GATA1s expression by 
NMD and significantly correlates with disease progression (Kanezaki et al., 2010). 
Mutations in the second category activate cryptic splice sites, sequences with similar 
degree of consensus matching as authentic splice sites but rarely if ever used for splicing 
(Sun and Chasin, 2000). An intronic segment, or pseudoexon, integrates into the mRNA 
and often leads to disruption of the open reading frame or incorporation of a premature 
termination codon. This type of error is reported in a variety of diseases, including mild 
hemophilia A, ocular albinism, Gitelman’s syndrome, respiratory disease, and melanoma 
(Pezeshkpoor et al., 2013; Naruto et al., 2015, Lo et al., 2011; Agrawal et al., 2012; 
Harland et al., 2001). Mutations in the third category lead to increased or decreased 
inclusion of an alternative exon by disrupting splicing enhancers or silencers. Alternative 
splicing is tightly regulated to produce normal ratios of natural mRNA isoforms. 
Disruption of tau protein isoforms, for example, underlies frontotemporal dementia and 
Parkinsonism linked to chromosome 17 (D’ Souza et al., 1999). Finally, insertion of 
transposable elements leads to aberrant splicing through alternate use of splice sites and 
generally produces nonfunctional proteins. In Fukuyama muscular dystrophy, inclusion 
of a new exon from a transposable element in the fukutin gene results in a mislocalized 
and nonfunctional protein (Taniguchi-Ikeda et al., 2011) 
The intronic mutation in GATA1 replaces cytosine with thymine 24 nucleotides 
upstream of the last intron-exon boundary (Figure 2B). It does not disrupt the 5’ splice 
donor site, the 3’ splice acceptor site, or the branch point adenosine. It precedes a 
pyrimidine-rich region that could represent the polypyrimidine tract bound by U2-
auxiliary factors but is unlikely to disrupt these interactions, as C is substituted with U, 
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another pyrimidine. The mutation is 2 nucleotides downstream of a G4 run, a potential 
ISE, and 6 nucleotides upstream of a CAG motif, which may represent a potential 
alternative splice acceptor site. Its mechanism is not immediately revealing and exon 
skipping, intron retention, and activation of a cryptic acceptor site are all plausible. I 
hypothesized that genome editing is an effective approach to model this new disease and 
splicing alteration leads reduced expression of functional GATA1 that may produce the 
clinical features of the unusual anemia observed in our patients.  
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CHAPTER 2. CRISPR-Cas9 Recapitulates the GATA1 Intronic Mutation of the 
Dyserythropoietic Anemia with Additional Modifications 
 
RESULTS & DISCUSSION 
2.1 CRISPR-Cas9 offers the possibility of creating an isogenic human erythroid cell 
line with the mutation of interest in GATA1 
To model the novel dyserythropoietic anemia in a tractable system, I aimed to 
create human erythroid cell lines with the single nucleotide change in intron 5 of GATA1 
identified on targeted mutation analysis (ChrX:48,652,176 C>T in hg19) (Figure 2). The 
K562 cell line derived from a patient with chronic myelogenous leukemia in blast crisis 
has been used in numerous applications, including the differentiation of the 
hematopoietic cells (Lozzio and Lozzio, 1975; Naumann et al., 2000). Cellular models of 
human origin are preferable to mouse models as our lab has previously demonstrated 
interspecies transcriptional and splicing divergence in erythropoiesis (Ulirsch et al., 
2014). Notably, the occupancy sites of GATA1 and many other transcription factors are 
significantly more conserved between primary cells and erythroid cell lines derived from 
the same species than across species.    
My method of choice was to perform targeted genome editing via the RNA-
guided CRISPR-Cas9 nuclease system. This system can be leveraged to generate the 
single nucleotide mutation in GATA1 in the genome of K562 cells by simultaneous 
delivery of a Cas9 nuclease, a single-guide RNA (sgRNA), and an exogenous DNA 
repair template containing thymine in place of cytosine at the desired position. Once 
expressed in cells, Cas9 may induce DSBs near the intended site of mutation to enable 
incorporation of the single nucleotide change via HDR (Figure 1C). CRISPR-Cas9 
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provides an ideal approach to study the molecular mechanisms of this enigmatic mutation 
as it leaves the rest of the genome unperturbed.   
In my initial experiment, I designed sgRNAs 1-4 using the Optimized CRISPR 
Design tool developed by the Feng Zhang Lab at MIT (Figure 4A-B). I prioritized guides 
that minimized the distance from the Cas9-mediated DSBs to the mutation site and the 
probability of off-target binding. All four guides have a computed score of 50 and above 
and are deemed high quality candidates based on faithfulness of on-target activity. The 
distance from the DSBs to the mutation site ranged from 10 to 27 bp (Figure 4C). As all 
four sgRNAs are oriented in the sense direction, I designed a sense single-stranded 
oligonucleotide donor (ssODN) as the repair template to avoid Cas9-mediated cleavage 
(Chen et al., 2011). The ssODN contains the thymine mutation with flanking sequences 
of 90 bp homologous to the target region (Ran et al., 2013). After cloning the sgRNAs 
into a plasmid vector, I selected sgRNAs 3 and 4 for direct nucleofection of K526 cells 
with Cas9 and ssODN (Figure 6A). These two guides have the shortest distance from the 
Cas9 cleavage site to the intended mutation, at 15 and 10 bp, respectively. The plasmid 
vector for Cas9 carries GFP and puromycin resistance genes, enabling both visual and 
chemical selection of successfully nucleofected cells (Figure 6B-C). After 48 hours of 
puromycin treatment, FACS analysis showed that 65.1% of an untreated K562 cell 
sample and 88.9% of a nucleofected K562 cell sample were propidium iodide (PI)-
negative, indicating greater survival in the latter group (Figure 6C). Many control cells 
remain PI-negative at this time point, as it may take longer for puromycin to cause cell 
death. Of the 88.9% of nucleofected K562 cells that are PI-negative, 92.2% were GFP+, 
indicating that most of the living cells are expressing Cas9. To isolate isogenic cell lines, 
  29 
I then performed serial dilutions based on the FACS estimates to achieve single cell 
plating for clonal expansion. To screen for the intended mutation, I purified DNA from 
26 clones nucleofected with sgRNA 3 and 20 clones nucleofected with sgRNA 4 for PCR 
amplification of the GATA1 target region and sequence analysis. Unexpectedly, all clones 
showed wild-type sequence of the target region with no evidence of genome editing in 
the form of insertion, deletion, or substitution (Figure 7A). As impaired GATA1 function 
may reduce cell survival, I then screened 9 slowest-proliferating clones nucleofected with 
sgRNA 4, which has the shortest cut-to-mutation distance and likely the highest 
probability for mutation incorporation (Kwart et al., 2017). Again, all clones showed 
wild-type sequence of the GATA1 target region (Figure 7A). Though sgRNAs typically 
work except on rare occasions for reasons not yet known (Ran et al., 2013), these results 
necessitate functional analysis of my sgRNAs. 
 
2.2 Surveyor nuclease assay identifies one guide RNA for targeted editing of GATA1 
 Surveyor nuclease is a special endonuclease that cleaves DNA with high 
specificity at sites of base substitution mismatch (Qiu et al. 2004). I harnessed this 
function to determine the ability of my sgRNAs to create targeted genomic modifications 
in GATA1 via CRIPSR-Cas9. For functional analysis of my sgRNAs, 293T cells provide 
a better system than K562 cells as they have high transfection efficiency and do not 
require GATA1 for survival. After transfecting 293T cells with sgRNAs 1-4 and GFP-
Cas9, I performed puromycin selection and harvested genomic DNA from each 
population for PCR amplification of the GATA1 target region. If CRISPR-mediated 
modifications were present, heat denaturation and reannealing of the amplified 
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heterogeneous DNA population would lead to formation of DNA heteroduplexes with 
mismatched bases at the site of Cas9 cleavage due to indels from NHEJ. Surveyor 
nuclease would then cleave the DNA heteroduplexes at the sites of mismatches to 
generate products smaller than the original PCR amplicon that can be visualized on a gel. 
 Using this assay, I found that sgRNAs 1-4 did not lead to CRISPR-mediated 
modifications in GATA1. In each reaction, only one band corresponding to the original 
PCR amplicon (397 bp) is present, suggesting that there were no indels in the target 
region and therefore no formation of DNA heteroduplexes or surveyor nuclease cleavage 
products (Figure 5C). The same result is seen when 293T cells are transfected with an 
sgRNA targeting another gene, ALAS2, which encodes delta-aminolevulinate synthase 2 
that catalyzes the first step in the heme biosynthesis pathway, or without an sgRNA 
(Cas9 only). Control G and Control C are plasmids with inserts that differ at a single base 
pair. As a positive control, I amplified a region containing this single base pair change 
and hybridized equal amounts of PCR products from both plasmids. As a negative 
control, I hybridized equal amounts of PCR products from Control C only. As expected, 
3 bands were present in the positive control, corresponding to G/G and C/C 
homoduplexes that were not cleaved by the surveyor nuclease (632 bp) and G/C and C/G 
heteroduplexes that were cleaved into products of 416 and 217 bp. Only 1 band is present 
in the negative control, corresponding to C/C homoduplexes that were not cleaved by the 
surveyor nuclease. These controls validate the function of the surveyor nuclease. 
 To ensure that the surveyor nuclease assay can confirm genome editing following 
CRISPR and that sgRNAs 1-4 did not lead to modifications of GATA1 due to their 
targeting sequences, I transfected 293T cells with an sgRNA targeting ALAS2 and 
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amplified the target region in ALAS2 for heteroduplex formation and surveyor nuclease 
digestion (Figure 5B). This sgRNA has been validated in prior CRISPR studies in our 
lab. As expected, the surveyor nuclease assay confirmed targeted editing of ALAS2 with 3 
bands corresponding to the wild-type PCR amplicon (713 bp) and digested products (387 
and 326 bp). If only Cas9 were transfected or if the amplified and reannealed products 
were not treated by the surveyor nuclease, only 1 band corresponding to the original PCR 
amplicon is present. These results suggest that GATA1 editing did not occur with sgRNAs 
1-4 due to their targeting sequences and not other variables in CRISPR. One possible 
reason is that sgRNAs 1-3 contain five consecutive thymine bases (Figure 4A). A poly-T 
signal can cause catalytic inactivation and backtracking of RNA Pol III (Nielsen et al., 
2013), leading to premature transcription termination of these sgRNAs. sgRNA 4 does 
not have a poly-T signal but has the most number of estimated off-target sites, which may 
contribute to the lack of GATA1 editing.  
 Next, I designed 5 new sgRNAs targeting GATA1. I included 3 sgRNAs oriented 
in the antisense direction to avoid the poly-T signal (sgRNAs 5-7) and 2 sgRNAs 
oriented in the sense direction targeting a region further upstream (sgRNAs 8-9). The 
distance from the Cas9-mediated DSBs to the mutation site ranged from 15 to 34 bp 
(Figure 4B). After cloning these new guides into a plasmid vector, I transfected 293T 
cells and performed functional analysis with the surveyor nuclease. Only sgRNA 5 
appeared to generate CRISPR-mediated modifications in GATA1, with evidence of 
surveyor nuclease digested products at 250 bp and 147 bp (Figure 6D). The 147 bp band 
is nearly undetectable, perhaps due to its small mass. sgRNAs 6-9 appear non-functional, 
with no clear evidence of surveyor nuclease digested products. Fortunately, among all 
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guides, sgRNA 5 has the lowest estimated number of off-target sites (Figure 4A). 
However, at 18 bp from the Cas9-mediated cleavage site to the intended mutation site 
(Figure 4C), generating a homozygous mutation may be inefficient. One study estimates 
that <10% of clones with evidence of HDR incorporated a homozygous mutation at this 
distance (Kwart et al., 2017). 
These experiments indicate that functional validation of sgRNA is a key step in 
performing genome editing with CRISPR-Cas9. They also highlight several limitations in 
finding an ideal guide, including 1) availability of unique targeting sequences adjacent to 
PAM sequences in the genomic region of interest to minimize off-target binding and 2) 
distance from the Cas9-mediated cut to the mutation site to optimize the likelihood of 
intended modification. Computational analysis may generate multiple promising sgRNA 
candidates but functional analysis may narrow the possibilities significantly. Antisense 
sgRNA targeting the transcriptionally active DNA strand may result in higher Cas9-
mediated cleavage and repair activity than sense sgRNA targeting the transcriptionally 
inactive DNA strand (Song and Stieger 2017). 
  
 
 
 
 
 
 
 
sgRNA Target Sequence Score* Offtargets Direction
1 5’-CTCCTTTTTGGCAGGTGAACCGG-3’ 68 211 Sense
2 5’-CCCGCAGCCTCCTTTTTGGCAGG-3’ 68 199 Sense
3 5’-GACACCCGCAGCCTCCTTTTTGG-3’ 67 170 Sense
4 5’-GAGAGGCAAAGGTCTGGAGTTGG-3’ 50 444 Sense
5 5’-GGCCGGTTCACCTGCCAAAAAGG-3’ 82 78 Antisense
6 5’-CGGTTCACCTGCCAAAAAGGAGG-3’ 70 105 Antisense
7 5’-TTTGCCTCTCTGTGTCAACCAGG-3’ 68 325 Antisense
8 5’-TGTCCCTGGTTGACACAGAGAGG-3’ 52 309 Sense
9 5’-GACACAGAGAGGCAAAGGTCTGG-3’ 50 478 Sense
5’...CAGCACCCAAAAATTATCTTACCCTGAAAGAAGTGGGGTAGAGAGGGTGTCCCTGGTTGA
CACAGAGAGGCAAAGGTCTGGAGTTGGGGACACCCGCAGCCTCCTTTTTGGCAGGTGAACC
GGCCACTGACCATGCGGAAGGATGGTATTCAGACTCGAAACCGCAAGGCATCTGGAAAAG...3’
A
B
*Inverse likelihood of off-target binding
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Figure 4. In silico analysis identifies multiple guide RNAs for targeted editing of GATA1
(A) Optimized CRISPR Design from Feng Zhang Lab at MIT identified 9 high quality sgRNAs (scores ! 50) 
with predicted Cas9-mediated cleavage within 35 bp of the mutation site. The guides are scored based on 
faithfulness of on-target activity, computed as 100% – weighted sum of offtarget hit-scores in the target 
genome. sgRNA 5 has the highest score at 82. Highlights, PAM sequences. Underlined, poly-T stretch. (B) 
Genomic locations of the unique PAM sequences corresponding to each sgRNA. The large red C 
represents the mutation site. (C) Number of nucleotides from predicted Cas9-mediated cleavage to the 
mutation site. sgRNA 4 is the closest, followed by sgRNA 3 and sgRNA 5. sgRNA 5, highlighted in red, is 
ultimately selected for targeted editing of GATA1.
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Figure 5. Surveyor nuclease assay identifies one guide RNA for targeted editing of GATA1
(A) 293T cells transfected with GFP-Cas9 and sgRNA. (B) Establishing the efficacy of the surveyor 
nuclease assay using an sgRNA known to produce targeted editing of ALAS2. This gene encodes delta-
aminolevulinate synthase 2, which catalyzes the first step in the heme biosynthesis pathway. Genomic DNA 
harvested from 293T cells transfected with ALAS2 sgRNA and Cas9 vs. Cas9 only are amplified with 
primers flanking the target region, heated to 95°C and cooled to 25°C to allow for DNA heteroduplex 
formation, and then treated with or without surveyor nuclease S, which cleaves DNA at mismatches. 
Ladder, 1 kb plus. PCR amplicon: 713 bp. Expected cleavage products based Cas9 cut site and indel 
(mismatch) formation: 387/326 bp. (C-D) Surveyor nuclease assay of GATA1 sgRNA 1-9. PCR amplicon: 
397 bp. Expected cleavage products: 259/138 bp (sgRNA1), 251/146 bp (sgRNA2), 247/150 bp (sgRNA3), 
223/174 bp (sgRNA4), 250/147 bp (sgRNA5), 217/180 bp (sgRNA6), 199/198 bp (sgRNA7), 206/191 bp 
(sgRNA 8), and 217/180 bp (sgRNA9). Control G/C heteroduplex, assay positive control. PCR amplicon: 
632 bp. Expected digested products: 416 and 217 bp. Control C homoduplex, assay negative control.
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Figure 6. CRISPR-Cas9 offers the possibility of creating an isogenic human erythroid cell line with 
the mutation of interest in GATA1
(A) Schematic of targeted genome editing and generation of isogenic K562 cell lines. Step 1: nucleofect 
K562 cells with GFP-Cas9, sgRNA, and repair template with the single nucleotide mutation. Step 2: treat 
with puromycin to select for cells expressing GFP-Cas9. Step 3: dilute serially to distribute single cells in 
each well of a 96-well plate. Step 4: allow single cells to expand into observable clones under the 
microscope. Step 5: purify DNA from clones and screen for mutation of interest. (B) K562 cells nucleofected 
with GFP-Cas9, sgRNA, and repair template. (C) After 48 hours of puromycin, FACS analysis of 10,000 
events showed that 65.1% of untreated (control) K562 cells and 88.9% of nucleofected K562 cells are 
propidium iodide (PI)-negative and 92.2% of nucleofected PI-negative K562 cells are GFP+. All untreated 
K562 cells are GFP-. The proportion of nucleofected PI-negative cells that are GFP+ is used to determine 
the appropriate serial dilution.
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2.3 Increasing the ratio of DNA repair template to guide RNA to Cas9 dramatically 
improves GATA1 editing efficiency and diversity 
 After identifying sgRNA 5 as a viable option for GATA1 editing, I designed an 
antisense ssODN as the repair template to avoid Cas9-mediated cleavage directed by the 
guide’s antisense targeting sequence. The ssODN contains adenine, corresponding to the 
thymine mutation, with flanking sequences of 90 bp homologous to the target region. I 
then nucleofected K562 cells with GFP-Cas9, antisense ssODN, and sgRNAs 5 and 6 (I 
included 6 to confirm correct interpretation of the surveyor nuclease assay and rule out 
possibility that faint digested bands were present indicating functional status). Of the 20 
clones I generated from sgRNA 5, 4 (20%) showed indels at the Cas9 cleavage site: 1) a 
homozygous 1 bp insertion, 2) a homozygous 1 bp deletion, 3) a heterozygous 1 bp 
insertion and 1 bp deletion, and 4) a heterozygous 3 bp deletion (Figure 7B). In contrast, 
all 31 clones generated from sgRNA 6 showed wild-type sequence of the GATA1 target 
region, suggesting that it is indeed a nonfunctional guide (Figure 7B).  
  Achieving targeted editing of GATA1 with sgRNA 5 is an important milestone. In 
order to create a single nucleotide mutation 18 bp from the Cas9 cut site, however, I 
needed to increase the editing efficiency from 20% and create conditions that favor the 
less efficient HDR pathway. I hypothesized that increasing the mass ratio of DNA repair 
template to sgRNA to Cas9 in the nucleofection reaction could be a simple and effective 
approach. In my next experiment, I nucleofected 10:3:1 µg of ssODN to sgRNA 5 to 
Cas9 per million K562 cells, compared to the previous 2:2:1 ratio (Figure 7C). 
Remarkably, at this new ratio, 106 of 133 (79.7%) clones I isolated with identifiable 
sequence patterns demonstrated targeted editing of GATA1 in at least one allele (Figure 
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7D). Furthermore, the diversity of GATA1 modifications increased substantially. The 
range of indel sizes increased from 1 to 3 bp at the low ratio to 1 to 136 bp at the high 
ratio (Figure 9-10). Incorporation of the desired C-to-T mutation via HDR occurred in 
both alleles in 3 clones and in one allele in 2 clones (Figure 11). In the following 
sections, I will describe insights that emerged from characterization of all newly 
produced GATA1 editing events. 
 
2.4 Most GATA1 edits occur within 15 bp of the Cas9 cleavage site and their 
distribution by genomic position reveals an upstream bias 
 Increased editing efficiency and diversity made many allelic combinations of 
GATA1 modifications possible. It became much more difficult to identify the exact 
sequences of both alleles in each clone by visualization of Sanger sequencing data alone. 
To determine the size and genomic location of each indel, I used 3 computational tools 
that can read chromatograms and characterize insertions and deletions by comparing an 
experimental file to a control file. Tracking of Indels by DEcomposition (TIDE) reports 
percent contributions and associated p-values of insertions and deletions by size 
(Brinkman et al., 2014). CRISP-ID aligns possible indels of different sizes to a target 
genomic region (Dehairs et al., 2016). Inference of CRISPR Edits (ICE) combines 
features of both methods and provides percent contributions of indels by size and 
genomic location relative to the Cas9 cut site (Hsiau et al., 2018).  
I analyzed GATA1 editing in each of my experimental clones by comparing them 
to a control clone nucleofected with Cas9 and repair template but no sgRNA. I expanded 
a total of 157 clones for DNA analysis and was able to determine the indel sizes and 
  38 
locations present in 133 clones. The remaining 24 clones had noisy data with inadequate 
alignment to the target sequence or unidentifiable indel. ICE was sufficient for analysis of 
110 clones. For each sample, it generates a discordance plot that shows where the 
experimental and control sequence traces converge and diverge (Figure 8A). For a 
homozygous clone, ICE shows 1 predominant indel of a specific size and Sanger 
sequencing shows 1 trace (Figure 8B). For a heterozygous clone, ICE shows 2 
predominant indels, one of which is often wild-type with 0 insertion or deletion, and 
Sanger sequencing shows 1 trace diverging into 2 traces in the edited region (Figure 8C). 
ICE also provides the genomic locations of the indels relative to the Cas9 cleavage site 
associated with sgRNA 5. In a homozygous clone, there is one major contributing 
sequence (Figure 8D). In a heterozygous clone, there are two major contributing 
sequences (Figure 8E). For the 23 clones that ICE failed to analyze, I was able to 
determine the indel sizes and locations using a combination of TIDE and CRISP-ID. 
Results from the 3 methods appear to correlate well for several high quality samples.  
 I mapped all modifications, including insertions, deletions, and substitutions, to 
the target region of GATA1 by position relative to the Cas9 cleavage site (Figure 9A). 
Insertions ranged from 1 to 5 bp and deletions ranged from 1 to 136 bp. I presented the 
two alleles of each clone consecutively for ease of association. I then summed all 
insertions and deletions at each nucleotide and divided the numbers by total aligned 
sequences (n = 266 alleles from 133 clones) to determine the frequency of indel by 
genomic position (Figure 9B). Collectively, the data reveal that the majority of GATA1 
edits occurred within 15 bp of the Cas9 cleavage site. Editing at each nucleotide beyond –
15 and +15 occurred at less than 3% frequency, except at the mutation site –18 from the 
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Cas9 cleavage site, which occurred at 5% frequency when the desired C-to-T 
substitutions are included with deletions.  
Notably, the distribution of indels by genomic position reveals an upstream bias 
of the GATA1 modifications. The editing frequency is higher upstream than downstream 
at each position equidistant from the Cas9 cleavage site (Figure 9B). Moreover, 3 
unusually large homozygous deletions (26 bp from –29 to –4, 120 bp from –121 to –2, 
and 136 bp from –133 to +2) and 1 usually large heterozygous deletion (91 bp from –80 
to +11) encompassed significant portions of intron 5 including the mutation site upstream 
of Cas9 cleavage. The boundary between intron 5 and exon 6 is located at +6-7 bp. One 
possible explanation for this upstream bias is that clones with homozygous indels 
downstream of the cut site have a survival disadvantage, as most of the downstream 
sequence is important for maintaining proper function of GATA1, via splicing regulation 
(e.g. the canonical splice acceptor site at +5-6) or translation into protein (e.g. the last 
exon begins at +7). Cells appear to tolerate upstream deletions of the intron better. 
Perhaps, proper splicing of GATA1 can still occur with significant alterations of the 
sequence context as long as key nucleotides or motifs are conserved.  
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Figure 7. Rigorous screening of guide RNA and optimization of the nucleofection reaction increased 
GATA1 editing efficiency from 0% to 79.7%
(A) No evidence of GATA1 editing in over 50 K562 clones generated with guide RNA 3 and 4 identified in 
silico, GFP-Cas9, and a repair template with the mutation of interest. Selective screening of slow-growing 
clones did not reveal any indels or single nucleotide replacement in the expected region. (B) Guide RNA 5 
identified in silico and in vitro with the surveyor nuclease assay produced K562 clones with targeted GATA1 
editing. Of the 20 clones screened, 4 had indels at the Cas9 cleavage site: 1) a homozygous 1 bp insertion, 
2) a homozygous 1 bp deletion, 3) a heterozygous 1 bp insertion and 1 bp deletion, and 4) a heterozygous 
3 bp deletion. In contrast to sgRNA 5, sgRNA 6 did not show definite activity in the surveyor nuclease 
assay. CRISPR using this guide did not produce any K562 clones with evidence of GATA1 editing. (C-D) 
Increasing the mass ratio of repair template to sgRNA to Cas9 from 2:2:1 to 10:3:1 in the nucleofection 
reaction dramatically improved GATA1 editing efficiency from 20% to 79.7%. The range of indel sizes also 
increased from 3 bp to over 100 bp. See Figures 9 and 10 for characterization of all editing events 
produced in these optimized conditions.
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Figure 8. Inference of CRISPR Edits (ICE) identifies allele-specific indels in isogenic cell lines
(A) Discordance plot generated by ICE (Hsiau et al., 2018). Control (orange tracing), Sanger sequencing of 
a K562 clone nucleofected with GFP-Cas9 and repair template but no sgRNA. Edited (green tracing), 
Sanger sequencing of a K562 clone nucleofected by sgRNA 5, GFP-Cas9, and repair template. The two 
traces are closely aligned until 10-20 bp from the predicted Cas9 cut site. (B) Homozygous clone. 15 bp 
deletion (-15) is the only indel present. Sanger sequencing shows 1 trace. (C) Heterozygous clone. Both 15 
bp deletion (-15) and wild-type sequence (0) are present. Sanger sequencing shows 1 trace diverging into 2 
traces in the edited region. (D) The homozygous clone has 1 significant contributing sequence. (E) The 
heterozygous clone has 2 significant contributing sequences. Horizontal dash, deleted nucleotides. Vertical 
dash, Cas9 cut site. Plus sign, wild-type sequence. 
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Figure 9. Most GATA1 edits occur within 15 bp of the Cas9 cleavage site and their distribution by 
genomic position reveals an upstream bias 
(A) Distribution of indel location. Each line represents the aligned sequence of an allele identified by ICE or 
a combination of TIDE and CRISP-ID (Brinkman et al., 2014, Dehairs et al., 2016). The two alleles of each 
K562 clone are mapped consecutively. Of note, encompassing the mutation site are 3 unusually large 
homozygous deletions (26 bp from -29 to -4; 120 bp from -121 to -2; 136 bp from -133 to +2) and 1 usually 
large heterozygous deletion (91 bp from -80 to +11). (B) Frequency of indel by position. Editing of the 
mutation site at -18 from DSB, including deletion (red) and the desired C>T substitution (not represented), 
occurred at 5% frequency. The intron-exon boundary is between positions +6 and +7. The editing frequency 
is higher upstream than downstream at each position equidistant from the DSB. 
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2.5 Most GATA1 edits occur within the intron and those that alter the canonical 
splice acceptor site or adjacent exon are exclusively heterozygous 
Consistent with upstream bias of GATA1 modifications, the majority (70%) of 
edited clones contain indels that map exclusively to intron 5 (Figure 10B). Even though 
exon 6 begins 7 bp from the Cas9 cleavage site, only a minority (30%) of edited clones 
contains indels that span both intron 5 and exon 6. Importantly, over a third (36%) of 
edited clones demonstrate homozygous editing of GATA1 (Figure 10C). However, all 
clones with deletion of the canonical splice acceptor site or exon 6 are heterozygous (n = 
35) (Figure 10D). These results further suggest that proper splicing and translation of 
GATA1, at least from one allele, is required for K562 cell survival.  
 The distribution of GATA1 indels by size shows that the most frequent 
modifications are 1 bp insertions followed by 1-2 bp deletions at the Cas9 cleavage site 6 
bp upstream of the intron 5-exon 6 boundary (Figure 10A). Curiously, the next most 
frequent editing event is a 15 bp intronic deletion –13 to +2 bp relative to the Cas9 
cleavage site. Its consistent genomic location and frequency comparable to 2 bp deletions 
argue against a completely stochastic process. Given its presence in both homozygous 
and heterozygous clones, this defined region does not appear to be essential for cell 
survival and may in fact be selected for deletion. Further inspection reveals that this 
intronic deletion encompasses a potential alternative splice acceptor site (YAG, where Y 
is a pyrimidine, or C in this case) as well as the PAM sequence of sgRNA 5 (CCT in the 
sense strand corresponds to AGG in the antisense strand detected by Cas9) and the first 5 
bp of its 3’ seed sequence. 
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Figure 10. Most GATA1 edits occur within the intron and those that alter the canonical splice 
acceptor site or adjacent exon are exclusively heterozygous 
(A) Distribution of indel size. Insertions range from 1 to 5 bp. Deletions range from 1 to 136 bp. Other than 
indels of 1-2 bp, a 15 bp deletion is the most frequently observed editing event. Most of the 15 bp deletions 
span -13 to +2 relative to the Cas9 cleavage site, which encompass an alternative splice acceptor site 
(purple) and sgRNA 5 PAM sequence (orange) but leave the canonical splice acceptor site (blue) intact. (B) 
The majority of indels are localized within the intron, even though exon 6 is only 7 bp from the Cas9 
cleavage site. (C) Over a third of all edited clones have homozygous indels. (D) All clones with deletion of 
the canonical splice acceptor site or the adjacent exon are heterozygous.
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2.6 The desired C-to-T intronic mutation in GATA1 co-occurs with additional 
modifications such as deletion of the guide RNA PAM sequence and a potential 
alternative splice acceptor site  
 Among the 133 clones with identifiable sequence patterns, I found 3 clones with 
homozygous C-to-T mutation (Mutants 1-3) and 2 clones with heterozygous C-to-T 
mutation (Mutants 4-5) at the desired genomic position (Figure 11A). In addition to 
substitution, editing at this position includes 3 unusually large homozygous deletions 
ranging from 26 to 136 bp and 1 unusually large heterozygous 91 bp deletion described 
previously (Figure 9A, Figure 11B). Interestingly, the homozygous C-to-T mutation co-
occurred in Mutants 1-2 with the frequently observed 15 bp deletion –13 to +2 bp from 
the Cas9 cleavage site, spanning a potential alternative splice acceptor site and the 
sgRNA 5 PAM and 3’ seed sequences (Figure 11C). It co-occurred in Mutant 3 with a 
novel C-to-A homozygous mutation between the potential alternative splice acceptor site 
and the PAM sequence. The heterozygous C-to-T mutation could be located on either 
allele so it is difficult to identify its associated downstream modifications. No additional 
modification is possible when an otherwise wild-type allele is present, as in Mutant 4. 
 Both technical and biological reasons can explain the presence of additional 
modifications in isogenic cell lines that have recapitulated the desired C-to-T mutation in 
GATA1. From a technical perspective, the error-prone NHEJ pathway occurs much more 
frequently than the high-fidelity HDR pathway, which is generally active only in dividing 
cells (Saleh-Gohari and Helleday 2004). Alleles that incorporated the mutation via HDR 
can undergo repeated editing by CRISPR-Cas9 until the target locus is rendered 
unrecognizable to sgRNA via indels from NHEJ. Concurrent deletion of the sgRNA 5 
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PAM sequence and 3’ seed sequence essential for target binding and Cas9 cleavage 
supports this phenomenon. One may be able to overcome this obstacle by enhancing the 
efficiency of HDR or blocking recurrent RNA-guided Cas9 editing. Recent approaches to 
enhancing HDR include cell cycle synchronization (Lin et al., 2014, Yang et al., 2016) 
and ssODN optimization with asymmetric 5’ and 3’ homology arms (Richardson et al., 
2016). To isolate a desired mutation and block additional modifications, Kwart et al. 
(2017) developed a framework named CORRECT consisting of two rounds of genome 
editing (Kwart et al., 2017). During the first round, the desired mutation is generated 
along with a CRISPR/Cas-blocking mutation positioned in the PAM sequence (re-Cas) or 
3’ seed sequence of the target sgRNA (re-Guide) using a repair template with both 
mutations. During the second round, the CRISPR/Cas-blocking mutation is erased using 
VRER-Cas9 (re-Cas), a Cas9 variant that recognizes the previously altered PAM 
sequence, or a modified sgRNA (re-Guide) that recognizes the previously altered 3’ seed 
sequence, and a repair template with the desired mutation only (Kleinstiver et al. 2015). 
The authors performed CORRECT in human pluripotent stem cells and estimate that 
generation of scarlessly edited isogenic cell lines requires approximately 3 months. 
  From a biological perspective, it possible that isogenic cell lines with the 
homozygous C-to-T mutation are at a survival disadvantage and additional modifications 
are required to “rescue” this defect. I hypothesized that this intronic mutation causes the 
distinct dyserythropoietic anemia observed in our patients via altered splicing of GATA1 
leading to reduced level of the functional protein. Remarkably, both Mutant 1 and Mutant 
2 with the desired homozygous mutation have an accompanying 15 bp deletion –13 to +2 
bp from the Cas9 cleavage site. The consistency of this genomic location suggests that 
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they are not random events as one might expect with indels from NHEJ. These 15 
deletions include 6 bp upstream of the sgRNA 5 PAM sequence and 3’ seed sequence not 
involved in targeting of CRISPR-Cas9. Interestingly, present in this 6 bp region is a 
potential alternative splice acceptor site (CAG). The C-to-T mutation may cause altered 
splicing and loss of function of GATA1 via aberrant activation of this alternative splice 
acceptor site and a partial intron retention event. Previously, I have discussed that K562 
cells may require at least one functional copy of GATA1 for survival, given an upstream 
intronic bias of all targeted editing events and lack of homozygous clones with alteration 
of the canonical splice acceptor site or adjacent exon (Figures 9-10). If the desired 
homozygous C-to-T mutation renders both copies of GATA1 nonfunctional and K562 
cells indeed require some level of functional GATA1 for survival, then it might be 
biologically impossible to isolate isogenic cell lines with only the desired mutation. The 
additional modifications may rescue the splicing defect via deletion of the potential 
alternative splice acceptor site (Mutants 1-2) or spontaneous mutation of a nearby 
nucleotide (Mutant 3) to preserve proper splicing and function of GATA1.    
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Figure 11. The desired C-to-T intronic mutation in GATA1 co-occurs with additional modifications 
including deletion of the guide RNA PAM sequence and a potential alternative splice acceptor site 
(A) Sanger sequencing of K562 clones with the desired C>T mutation in the last intron of GATA1. Control, 
nucleofected with GFP-Cas9 and and repair template but no sgRNA. Mutants 1-3, homozygous T/T. 
Mutants 4-5, heterozygous C/T. (B) All types of editing at the desired genomic location. The 4 clones with 
large deletions spanning this position are described in Figure 9A. (C) TIDE analysis of Mutants 1-5. 
Homozygous C>T mutation co-occurred in 2 clones with a 15 bp deletion including the sgRNA 5 PAM 
sequence and a potential alternative splice acceptor site and in 1 clone with a C>A mutation 2 bp from the 
potential alternative splice acceptor site. Pink bars, significant indels (p < 0.001) and its % representation. 
Black bars, insignificant indels (p ! 0.001). Modified sequences: strikethrough, deleted; blue, canonical 
splice acceptor site; purple, alternative splice acceptor site; orange, sgRNA 5 PAM sequence; green, SNP.
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METHODS 
Cloning of single guide RNA constructs 
The human GATA1 gene sequence was obtained from NCBI and a 100-bp region 
centering on the mutation site of interest (chrX: 48,652,176) was submitted to Optimized 
CRISPR Design developed by the Feng Zhang laboratory at MIT for identification of 
appropriate sgRNAs. Targeting sequences with computed scores #50 were considered 
high quality based on faithfulness of on-target activity. Nine sgRNAs with the highest 
scores and the shortest distance from the predicted Cas9 cleavage site to the mutation site 
were selected as candidates for experimentation (Figure 4). Two sets of oligonucleotides 
were purchased for each sgRNA: 1) the top strand of contains GTTTT 3’ overhang 
complementary to CAAAA in the linearized vector and constitute the first 5 bases of 
tracrRNA; 2) the bottom strand contains CGGTC 3’ overhang complementary to 
CACCG in the linearized vector and constitutes the last 4 bases of the U6 promoter and 
the first base required for PolIII transcription start site. For cloning into the pSg1 plasmid 
vector (GenScript), 0.5 µg of the plasmid was digested with 5U BplI in 1X Tango Buffer 
supplemented with 0.05 mM S-adenosylmethionine (SAM) for 2 hours at 37°C, purified 
with QiaQuick columns (Qiagen), re-digested with 5U NheI in NEB Buffer 2.1 for 1 hour 
at 37°C, dephosphorylated with FastAP thermosensitive alkaline phosphatase (Thermo 
Fisher) for 15 min. at 37°C, and then purified again with QiaQuick columns (Qiagen). 
Meanwhile, the sgRNA oligos were each diluted to 20 µM in 5 µl water, heated to 85°C, 
snap cooled on ice, and then phosphorylated with T4 polynucleotide kinase (NEB) at 
37°C for 30-60 min. The phosphorylated top and bottom oligos were mixed and then 
denatured and annealed using the following temperature series: 98°C for 2 min., 85°C for 
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2 min., 75°C for 5 min., 65°C for 5 min., and room temperature. The digested pSg1 
plasmid backbone and phosphorylated and annealed oligos were ligated with T4 DNA 
ligase (NEB) at room temperature for 15 min. For transformation, each ligation reaction 
was added to 10 µl of chemically competent E. coli (Invitrogen™), heat shocked at 42°C 
for 40 seconds, and then returned to ice. Transformed bacteria were shaken in 500 µl LB 
media at 37°C for 45-60 min. and then plated on LB agar plate with ampicillin overnight. 
The next day, colonies were inoculated in 3 mL ampicillin-supplemented LB media and 
shaken at 37°C for 24 hours. Plasmid DNA was isolated by miniprep (Qiagen) and 
sequenced for identification of integrated sgRNA*. For mass production of plasmids 
carrying sgRNA, clones confirmed by sequencing were expanded for maxiprep (Qiagen).     
*Sequencing primer: 
U6 forward primer: 5’-TGTACAAAAAAGCAGGCTTTAAAGG -3’ 
 
Functional validation of single guide RNA constructs 
 293T cells were cultured in DMEM (Gibco™) with 10% FBS and 1% penicillin-
streptomycin. For functional validation of each sgRNA construct, 300,000 cells were 
transfected with 0.66 µg sgRNA (cloned pSg1 plasmid) and 0.33 µg GFP-Cas9 
(pXPR_001 plasmid from Feng Zhang) in Opti-MEM (Thermo Fisher) with FuGENE 
(Promega). 24 and 48 hours after transfection, puromycin was added to fresh media at a 
final concentration of 2 µg/ml for selection of cells that have been successfully 
transfected. 72 hours after transfection, the cells were harvested for genomic DNA 
extraction (Qiagen). For the surveyor nuclease assay (IDT), the target genomic region in 
GATA1 was first amplified by PCR*, along Control G and Control C plasmids with 
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premixed primers. After purification, DNA heteroduplexes were generated using the 
following temperature series: 95°C for 10 min., -2.0°C per second from 95°C to 85°C, 
and then -0.3°C per second from 85°C to 85°C to 25°C. The entire cooling process took 
about 20 min. total. Equal amounts of Control C and Control G were mixed for the assay 
positive control. Only Control C was present in the assay negative control. The annealed 
heteroduplexes were then digested with Surveyor Nuclease S and Surveyor Enhancer S in 
water with 0.15M MgCl2 at 42°C for 60 min. The digested products were visualized on 
2% agarose gel. Electrophoresis was stopped after the dye has migrated about 1/3 of the 
length of the gel for the purpose of photographing the gel early in the run. Then 
electrophoresis was continued until the dye has migrated 2/3 of the length of the gel. 
*PCR primers:  
GATA1 forward primer: 5’-CCTCCTCCTTCCTCTCCTCT-3’ 
GATA1 reverse primer: 5’ CACCACCATAAAGCCACCAG-3’ 
 
Genome editing and generation of K562 isogenic cell lines  
K562 cells were cultured in RPMI 1640 medium (Gibco™) with 10% FBS and 
1% pencillin-streptomycin. On the day prior to nucleofection, they were plated at a 
density of 250,000 cells/mL without antibiotics. For genome editing with CRISPR/Cas9, 
1 million cells were resuspended in Supplemented Nucleofector® Solution (Lonza) with 
either 2 µg DNA repair template (single-stranded oligo donor with intended mutation 
flanked by 90-bp homology arms), 2 µg sgRNA, and 1 µg GFP-Cas9 (low ratio) OR 10 
µg DNA repair template, 3 µg sgRNA, and 1 µg GFP-Cas9 (high ratio). The cell 
suspensions were then transferred to a certified cuvette and placed in a standard device 
  52 
for nucleofection (Nucleofector® Program T-016 for K562 cells). After nucleofection, 
the cells were transferred back to its normal growth media and incubated in a humidified 
37°C/5% CO2 chamber. 24 and 48 hours after nucleofection, puromycin was added to 
fresh media at a final concentration of 2 µg/ml for selection of cells that have been 
successfully nucleofected. 72 hours after nucleofection, the cells were resuspended in 
media without puromycin. 96 hours after nucleofection, 300 µL of each sample was 
collected, centrifuged, and resuspended in FACS buffer with propidium iodide (PI). 
FACS was performed to determine the percentage of PI-negative cells (indicating 
survival) that were GFP+ (indicating Cas9 expression), which informed subsequent serial 
dilutions, i.e. if there were 100,000 cells initially and 60% PI-negative cells are GFP+, I 
used 60,000 as the starting number. Cell suspensions were serially diluted from the 
starting number to 50,000/mL, 5,000/mL, 500/mL, and 10/mL to achieve single cell 
plating. The 96-well plates were then incubated for 10-14 days and screened under light 
microscope for identification of well-defined single colonies in each well. All equivocal 
single colonies and double or triple colonies were excluded from further analysis. Single 
colonies were then transferred to larger plates for clonal expansion. 
 
Screening for GATA1 mutation and DNA sequencing analysis 
Expanded clones were harvested for genomic DNA extraction (Qiagen) followed 
by PCR amplification and sequencing of the GATA1 target region*. Sanger sequencing 
chromatograms were analyzed using ICE (Hsiau et al., 2018). If ICE failed to align the 
sequences, a combination of TIDE and CRISP-ID were used to identify allele-specific 
alterations (Brinkman et al., 2014; Dehairs et al., 2016). The control clone used in these 
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methods was nucleofected with GFP-Cas9 and DNA repair template but no sgRNA. All 
modifications were mapped by genomic position on Microsoft Excel and editing 
frequencies at each position was determine by dividing the total number of editing events 
at that position by total number of alleles. 
*PCR primers: 
GATA1 forward primer: 5’-CCTCCTCCTTCCTCTCCTCT-3’ (also sequencing primer) 
GATA1 reverse primer: 5’ CACCACCATAAAGCCACCAG-3’ 
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CHAPTER 3. Impaired human hematopoiesis due to a cryptic intronic GATA1 
splicing mutation*  
 
*Adapted from paper in preparation for submission (some components are incomplete) 
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ABSTRACT 
Recent studies of allelic variation underlying genetic blood disorders have 
provided important insights into human hematopoiesis. In the majority of instances, such 
pathogenic mutations result in complete loss-of-function or missense changes. It can be 
challenging to assess the pathogenicity of non-coding variants. Here, we characterize two 
unrelated patients with a distinct presentation of dyserythropoietic anemia and disordered 
hematopoiesis associated with an intronic mutation in GATA1 that is 24 nucleotides 
upstream of the canonical splice acceptor site. Functional studies demonstrate that this 
single nucleotide alteration leads to reduced canonical splicing and increased use of an 
alternative splice acceptor site that causes a partial intron retention event. The resultant 
altered GATA1 protein due to this intron retention event – involving a 5 amino acid 
insertion between the two zinc fingers - has no observable function. Collectively our 
results demonstrate how altered splicing of GATA1, which leads to overall reduced 
levels of the normal form of this master hematopoietic transcription factor, can result in 
distinct alterations in hematopoiesis, with potential implications for more common 
acquired blood disorders due to splicing factor mutations, such as the myelodysplastic 
syndromes.  
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INTRODUCTION 
While hematopoiesis is arguably one of the best-understood paradigms of cell 
differentiation in physiology, many facets of this process remain poorly understood. 
Genetic blood disorders provide an opportunity to learn more about hematopoiesis, even 
in cases where a mutated gene has been previously well studied, since allelic variation 
can provide novel biological insights (1-5). Advances in sequencing technologies have 
enabled rapid and efficient mutation identification, but deciphering the pathogenicity of 
non-coding variation can be immensely challenging. Non-coding transcriptional 
regulatory elements can be interrogated using a number of functional approaches, 
including the use of genome editing and exogenous assays of regulatory function (6-8). 
However, deciphering the pathogenicity of cryptic splicing mutations can present 
substantial challenges (9, 10).  
Here we have identified two unrelated patients with a unique form of 
dyserythropoietic anemia that is associated with other abnormalities in hematopoiesis. 
Both of the patients harbor identical intronic mutations in GATA1. Through functional 
studies, we show that this single nucleotide change leads to altered splice acceptor usage 
and overall decreased splicing efficiency, thereby resulting in the disease phenotype. This 
mutation disrupts the activity of the U2 splicing complex in the last intron of GATA1, 
providing a potential connection between these rare forms of impaired hematopoiesis and 
more commonly observed cases of myelodysplastic syndrome (MDS), which are 
attributable to somatic mutations in this splicing regulatory complex itself (11). In 
addition, our study illustrates how decreasing the splicing efficiency of the hematopoietic 
master regulator GATA1 can impair selective aspects of human hematopoiesis and lead 
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to distinct phenotypes when compared with other pathogenic mutations affecting the 
same gene (12-14). 
 
RESULTS & DISCUSSION 
In the course of studying a cohort of patients with rare genetic blood disorders, we 
encountered two patients who both had a dyserythropoietic anemia that necessitated 
transfusions in early infancy with subsequent evolution into a milder anemia that was 
noted to worsen in the setting of intercurrent illnesses. Bone marrow evaluation of the 
patients revealed dyserythropoiesis, along with frequent small hypolobulated 
megakaryocytes and occasional dysplastic myeloid cells (Figure 1A, Supplemental 
Figure 1). Platelet function testing in Patient 1, who was noted to have clinical bleeding, 
revealed specific impairments, including defective aggregation and "-/$-granule secretion 
(as indicated by decreased expression of P-selectin/ CD62 and LAMP-3/ CD63), which 
are suggestive of defective thrombopoiesis (Figure 1B and Supplemental Figure 1). 
Further clinical details of the 2 patients are described in the Methods and in the 
supplemental material. To assess the etiology of the impaired hematopoiesis in these 
patients, whole exome sequencing (WES) and targeted mutation analysis were 
performed. No known blood disorder-associated mutations were identified, but both 
patients were noted to have a unique mutation in the fifth intron of GATA1 
(ChrX:48,652,176 C>T in hg19) that was carried in the mothers of these patients (Figure 
1C, Supplemental Figure 2). This mutation was absent from the 123,136 exomes and 
15,496 genomes in the gnomAD database, despite excellent coverage of this region 
(Supplemental Methods). 
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The identified mutation was located 24 nucleotides upstream of the canonical 
splice acceptor site in the fifth intron of GATA1. While the mutation was not predicted to 
disrupt known splicing elements, we hypothesized that it may impair appropriate splicing 
of this gene. To directly interrogate this, we utilized a minigene reporter assay to examine 
how this single nucleotide alteration may impact splicing (Figures 2A, B) (15). We 
found that the mutation reduced normal splicing of this region of GATA1 and promoted 
an intron retention event of 15 nucleotides involving an alternative splice acceptor site 
(Figure 2B). Semi-quantitative RT-PCR analysis revealed a reduction of canonical 
GATA1 splicing to 42% of normal levels, with the mutant mRNA at 36% of normal levels 
(Figure 2C). Importantly, we could confirm this altered splicing was present in the 
patient samples, but was found at significantly lower levels in healthy controls (Figure 
2D). Throughout human erythroid differentiation (7, 16), there was no major variation in 
GATA1 splicing that could be identified (Figure 2E, Supplemental Figure 3), 
suggesting that the altered splicing observed in these cases was attributable to the 
distinctive pathogenic variants.  
We wanted to further investigate the underlying mechanisms for the altered 
splicing present due to these pathogenic mutations. It was interesting that the observed 
alternative splice acceptor site usage with resultant intron retention (Figure 2F) was 
similar to what is frequently observed in SF3B1-mutated MDS, where there is alternative 
splice acceptor site usage in a number of transcripts between approximately 15 and 25 
nucleotides upstream of the canonical splice acceptor site (17, 18).  Given the phenotypic 
similarity between MDS and the disordered hematopoiesis observed in these patients, as 
well as the likely involvement of the U2 splicing complex in the region where this 
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mutation resided, we decided to test whether the commonly observed SF3B1 K700E 
mutant, which is known to impair U2 splicing activity, would further impair the observed 
altered splicing due to this intronic GATA1 mutation. Using the minigene assay described 
above, we found that expression of the SF3B1 K700E mutant markedly impaired splicing 
of the mutant GATA1 and led to near complete alternative splice acceptor usage. This 
finding shows that the observed germline mutation in these patients directly impairs 
activity of the U2 splicing complex in this region of GATA1. We examined whether 
SF3B1-mutated MDS cases (with a diagnosis of refractory anemia with ringed 
sideroblasts) may have altered splicing or levels of GATA1, but we did not observe 
consistent defects suggesting altered splicing or the presence of reduced levels of GATA1 
mRNA, even in sorted stage-matched bone marrow populations (Supplemental Figure 
4). However, it is possible that a potential defect may be present and detection of this 
may be masked due to selective survival of or selection for cells that have normal GATA1 
splicing.  
To gain further insight into the mechanism by which the GATA1 intronic mutant 
disrupts human hematopoiesis, we examined whether the protein produced from the 
intron retention event – which would add 5 additional amino acids between the N and C-
terminal zinc fingers of GATA1 – may have altered activity (Figure 3A). In an 
exogenous setting, we found that both RNA levels (as inferred through the expression of 
a linked GFP molecule that is translated from an internal ribosome entry site on the same 
transcript) and protein levels (as measured directly) of this mutated cDNA were stable 
and similar to what is observed with wild type GATA1 cDNA (Figure 3B). Exogenous 
expression of the mutated cDNA in primary human hematopoietic stem and progenitor 
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cells (HSPCs) induced to undergo erythroid differentiation revealed that the mutated 
form failed to promote precocious erythroid differentiation, as occurs with the wild type 
cDNA, but concomitantly there was no dominant negative activity observed in this 
setting where wild type GATA1 protein is present (Figure 3C) (6, 19, 20). These results 
suggest that the mutated protein formed by this intron retention event is inactive. To 
directly assess this, we used a Gata1-null mouse cell line, G1E, to complement this 
phenotype with either the wild type or mutant cDNAs (14, 21). While the wild type 
cDNA robustly promoted erythroid differentiation in this setting, the mutant form failed 
to do so, directly showing that this mutated protein produced from an intron retention 
event displays complete loss-of-function (Figure 3D, Supplemental Figure 5). Together 
with the data shown above from the interrogation of splicing, these results demonstrate 
that the impaired hematopoiesis in these cases emerges due to reduced expression of 
GATA1 to ~40% of normal levels with the production of an inactive mutant protein due 
to the intron retention event we observed. 
Our findings have several important and broad implications. While cryptic 
splicing mutations can be challenging to study, we illustrate how by using a series of 
functional assays, the mechanisms underlying such mutations can be more fully 
understood. Exactly how the activity of the U2 splicing complex is disrupted in these 
cases remains uncertain, but given the lack of consensus binding sequences, no clear-cut 
mechanisms have been apparent. Given the finding of interactions between a mutant form 
of SF3B1 commonly observed in MDS cases and the germline mutation we identified, as 
well as the phenotypic similarity between these disorders, it is interesting to speculate 
about potential connections between these observations. We have not been able to 
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demonstrate aberrant GATA1 mRNA splicing or expression in MDS cases in our 
analyses, but it is possible that we may be limited due to selection for cells lacking such 
an impairment. The phenotypic similarities are particularly compelling, given the 
observed perturbations of GATA1 protein levels that have been reported in MDS patient 
samples and this will be an important area for future investigation (22). Our findings also 
demonstrate how by reducing the overall levels of GATA1, a distinct defect in human 
hematopoiesis can emerge. Missense mutations in GATA1 can result in dyserythropoiesis, 
thalassemia, and a variety of thrombopoietic defects (12). Lack of the full-length form of 
GATA1 with continued production of the short isoform can cause Diamond-Blackfan 
anemia (13). We have recently found that impaired translation of GATA1 in early 
hematopoietic progenitors underlies the more commonly observed cases of Diamond-
Blackfan anemia due to ribosomal protein mutations (19). Moreover, such aberrant 
translation of GATA1 may also occur in other blood disorders, such as myelofibrosis 
(23). The results we describe in this paper extend the spectrum of these phenotypes and 
show how distinct alleles in a single key regulator of hematopoiesis can cause pleiotropic 
phenotypes, illustrating the numerous functions of GATA1 in normal human 
hematopoiesis. 
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Figure 1. Identification of a GATA1 intronic mutation in two unrelated patients 
with dyserythropoietic anemia. (A) Images of bone marrow aspirates from Patient 1 
and 2. (B) The thrombin-induced expression of CD62 and CD63 on platelets from 
Patient 1 or a healthy control was detected by flow cytometry. There is defective 
expression of these antigens, indicating an !-/"-granule deficiency. (C) Sequencing 
chromatograms of mutation in GATA1 (ChrX:48,652,176 C>T in hg19) from a healthy 
control, the two patients, and their mothers.
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Figure 2. Decreased canonical splicing and intron retention due to a pathogenic 
GATA1 mutation. (A) Schematic of the minigene assay involving exons 5 and exons 
6 of GATA1. The minigene vector, pSpliceExpress includes two exons from Rat 
Insulin (Rat Ins Ex) as a control for splicing, a SV-40 promoter (Prom), and a 
polyadenylation site (PolyA) (B) Representative RT-PCR from the minigene assay in 
the presence or absence of the mutation shows the reduction of canonical splicing 
and presence of an intron retention event, which was confirmed through cloning and 
Sanger sequencing of the resultant products. (C) Semi-quantitative RT-PCR analysis 
of the minigene assay using 28, 30, 32, and 34 PCR cycles. The bar graph (below) 
depicts quantified levels of the various products, including the total amount of GATA1 
(red), the amount of the wild type (WT) band (blue), or the amount of the mutant (Mut) 
band in the setting of the mutation involving an intron retention event (***P< 0.001). 
(D) RT-PCR analysis of GATA1 exon 5 and exon 6 from control and patient peripheral 
blood mononuclear cells. (E) Representative RT-PCR analysis of GATA1 exon 5 and 
exon 6 from human HSPCs undergoing erythroid differentiation. (F) Schematic 
demonstrating alternative splicing in the 5th intron of GATA1, including the location of 
the intronic mutation and the nucleotides involved in intron retention (red). The 
splicing patterns are depicted above with a red dashed or solid black line. (G) RT-
PCR analysis of the minigene assay performed, as above, or with increased 
expression of wild type (WT) SF3B1 or the K700E SF3B1 mutated protein. 
65 
Figure 3
untransfected
GATA1 WT
GFP
GATA1 Mut
B
C
GAPDH
GATA1
unt
ran
sfe
cte
d
em
pty
 ve
cto
r
GA
TA
1 W
T
GA
TA
1 M
ut
Co
un
t
CD
49
d
CD
71
GATA1 WT GATA1 Mut
CD235a
CD
49
d
CD
71
Control
43.6 64.6 54.555.9
0.43 0 0 00.30 0
45.335.9
72.420.7
0.366.53
82.810.3
6.70 0.18
73.019.1
7.32 0.61
99.00.58
0 0.37
0.78 96.9
2.2700 0.54
0.68 98.7
0.14
0.39
99.5
0
99.30.089
00.58
0.18 98.9
00.92
Day 12
Day 7
D
48 hours
72 hours
96 hours
Co
un
t
GATA1 WT GATA1 MutControl
Ter119
33.067.00.3499.7 0.4699.5
0.1299.9 33.067.0 0.4599.5
0.5099.5 50.349.7 2.7997.2
A
A GGGTTTTTTC CCCC
Pro Pro Phe Trp Gln
GAC GTG
Ex 5 Ex 6Retained Intron 5
Gln Val
Figure 3. GATA1 variant produced through the intron retention event is 
expressed, but shows no function. (A) Schematic shows insertion of 5 amino acids 
as a result of the intron retention event. (B) A histogram plot (left) shows GFP levels 
indicating robust expression of the RNAs (GFP linked to cDNA by internal ribosomal 
entry site). A representative western blot of GATA1 levels from exogenous cDNA 
expression is show (right).  (C) Representative flow cytometric assessment of 
erythroid differentiation (using CD235a, CD71, and CD49d) on day 7 and day 12 
during erythroid differentiation of human HSPCs upon exogenous expression of wild 
type (WT) GATA1 or the mutated GATA1 (Mut) protein. (D) Representative histogram 
plots assessing the marker of mouse erythroid differentiation, Ter119, in G1E cells 
infected with GATA1 WT or GATA1 Mut cDNAs after 48, 72, or 96 hours.
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Supplementary Figure 1
A
B
three additional smear images to go here
Agonist Maximum Aggregation (%) Color 
Collagen [2.0 μg/ml] 5.0 black 
Ristocetin [1.2 mg/ml] 56.3 red 
ADP [4 μmol/l] 1.2 blue 
Epinephrine [8 μmol/l] 0.7 green 
Supplemental Figure 1. Clinical phenotypes of patients with dyserythropoietic 
anemia and disorder hematopoiesis. (A) Histology images of bone marrow 
aspirates. (B) Platelet agglutination/aggregation analyses, as measured by light 
transmission, after stimulation with several agonists that are labeled in the table on 
the right.
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Supplemental Figure 2 
Patient 1
Mother 1
Patient 2
Supplemental Figure 2. Sequencing analysis of two unrelated patients with a 
distinct form of dyserythropoietic anemia. Integrated Genomics Viewer was used 
to visualize whole exome sequencing reads to verify the variant at position chrX: 
48652176 (hg19 coordinates) and the sequencing coverage in this region.  Patient 1 
and Patient 2 are hemizygous, while Mother 1 (mother of Patient 1) is a carrier of this 
mutation.
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Supplemental Figure 3
0
GATA1
GATA1
0
1000
2000
3000
500
1000
1500
2000
2500
3000
GATA1
GATA1
0
1000
2000
3000
0
500
1000
1500
2000
2500
3000
GATA1
GATA1
0
1000
2000
3000
0
500
1000
1500
2000
2500
GATA1
GATA1
0
500
1000
1500
2000
0
500
1000
1500
GATA1
GATA1
0
1000
3000
4000
0
500
1000
1500
2000
2500
3000
3500
2000
pr
oe
ry
th
ro
bla
st
ea
rly
 b
as
op
hil
ic
lat
e 
ba
so
ph
ilic
po
lyc
hr
om
at
ic
or
th
oc
hr
om
at
ic
GATA1
GATA1
Supplemental Figure 3. RNA-seq analysis of GATA1 splicing patterns during 
human erythropoiesis. RNA sequencing reads in the GATA1 locus during terminal 
erythroid differentiation are shown. The total reads spanning each exon are shown 
above each axis during each stage of differentiation. A Sashimi plot of junction 
spanning reads is shown below for each stage. No major changes in splicing or exon 
usage are noted throughout erythroid differentiation. 
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Supplemental Figure 4
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Supplemental Figure 4. Sorted bone marrow populations of SF3B1 mutated 
MDS samples or controls do not have detectable differences in GATA1 mRNA 
levels. (A) RT-PCR analysis of GATA1 exon 5 and exon 6 from CD34+ or 
CD71+CD235a+ sorted bone marrow cells from SF3B1 mutated MDS samples or 
healthy controls. GAPDH is used as a loading control. The top panels show gel and 
no appreciable levels of the intron retention event between exons 5 and 6 can be 
seen in the upper bands. The panels below show quantification of these gels using 
ImageJ. N.S. is non-significant. (B) Quantitative RT-PCR analysis of GATA1 exon 2 
and exon 3 from the same samples above normalized to ACTB.
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A B
Supplemental Figure 5
Supplemental Figure 5. G1E cells overexpressing GATA1 protein from intron 
retention event demonstrate delayed maturation. (A) Cytocentrifuge analysis of 
GFP+ sorted G1E cells overexpressing GATA1 WT cDNA, 48 hours after infection. (B) 
Cytocentrifuge analysis of GFP+ sorted G1E cells overexpressing GATA1 mutant 
cDNA 48 hours after infection. 
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METHODS 
Case Reports. 
Patient 1 was a boy born at full term to healthy unrelated parents from Bulgaria (mother) 
and Togo (father). On first day of life anemia with hemoglobin (Hb) of 9.4 g/dL and 
concomitant jaundice with elevated lactate dehydrogenase (LDH) were noted. Besides a 
second-degree hypospadias, no syndromic features were present. The patient required 
transfusions at 6 weeks and 3 months of age because of Hb drops to the 5 g/dL range with 
an inadequate reticulocyte response. Subsequently he maintained a stable Hb of 8-10 
g/dL with persistent red cell macrocytosis and a few giant platelets. At the age of 3.5 
years, a respiratory tract infection with febrile seizure occurred with transiently worsened 
anemia (Hb 6.3 g/dL, reticulocytes at 18%) and a mild thrombocytopenia (133,000 cells 
per microliter). The patient had elevated LDH with no signs of active hemolysis. 
Extensive evaluations performed during and between the acute episodes for non-immune 
hemolytic anemias, infectious, metabolic, and autoimmune disorders, as well as bone 
marrow failure syndromes (including mitomycin C induced DNA damage testing and 
telomere length measurements), were unrevealing. An erythrocyte adenosine deaminase 
level was elevated at 2.79 U/g Hb. Multiple bone marrow examinations revealed normal 
cellularity with signs of dyserythropoiesis with macrocytic and occasional megaloblastic 
differentiation, mild dysplasia of the megakaryocytic lineage with hypolobated forms, 
and hypogranulated neutrophils. Outside of occasional incurrent illnesses, the Hb 
remained stable at levels of 9-10 g/dl with macrocytosis (MCV ~100 fl) and a persistently 
elevated fetal Hb (~20-23%), while the platelet counts remained in the low normal range. 
At the age of 7, when presenting with Mycoplasma pneumonia, there was severe epistaxis 
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and moderate thrombocytopenia (45,000 cells per microliter), as well as platelet function 
abnormalities that persisted even as the platelet counts normalized. The family medical 
history was unremarkable with the exception of a maternal first cousin with a chronic 
anemia of unclear etiology.  
Patient 2: Awaiting clinical data 
 
The whole-exome sequencing data are available in the dbGaP database 
(http://www.ncbi.nlm.nih.gov/gap) under the accession number phs000474.v2.p1. 
 
Statistics. All pairwise comparisons were performed using the 2-tailed Student’s t test, 
unless otherwise indicated. Differences were considered significant if the P value was 
less than 0.05. 
 
Study approval. All family members provided written informed consent to participate in 
this study. The IRBs of Boston Children’s Hospital, Massachusetts Institute of 
Technology, the University of Michigan, and the University of Freiburg approved the 
study protocols. 
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SUPPLEMENTAL METHODS 
Platelet Aggregometry and Flow Cytometry 
Platelet agglutination/ aggregation were analyzed using the following agonists: ristocetin 
(1.2 mg/ml), collagen (2.0 µg/ml), adenosine diphosphate (ADP; 4.0 µmol/l), and 
epinephrine (8 µmol/l), as described previously (1). For flow cytometric analyses, 
diluted platelet rich plasma (5x107 platelets/ml) was stimulated with different 
concentrations of thrombin (0.025-1.0 U/ml) in the presence of 1.25 mM Gly-Pro-Arg-
Pro. Platelets were stained by monoclonal anti-CD62P (CLB-thromb/6-FITC) and anti-
CD63 (CLB-gran/12-FITC) antibodies and analyzed by flow cytometry as previously 
described (2). 
 
Whole Exome Sequencing & Related Genetic Analyses 
The patients described in this paper are part of a rare blood disorder cohort that has been 
studied through the use of whole exome sequencing (WES). WES was performed as 
previously described (3, 4). The resultant variant call file (in hg19 coordinates) was 
annotated with VEP v89 (5) and rare variants (based on ExAC v0.3.1 and GnomAD 
r2.0.2) (6) (http://gnomad.broadinstitute.org/) were identified using a combination of the 
Genome Analysis Toolkit, Bcftools, and Gemini (7-9). No rare (<0.01% allele frequency 
in ExAC and GnomAD) loss-of-function or missense variants were identified in any 
known red blood cell disorder genes (ANK1, SPTB, SPTA1, SLC4A1, EPB42, EPB41, 
PIEZO1, KCNN4, GLUT1, G6PD, PKLR, NT5C3A, HK1, GPI, PGK1, ALDOA, TPI1, 
PFKM, ALAS2, FECH, UROS, CDAN1, SEC23B, KIF23, KLF1, GATA1, HBB, 
HBA1, HBA2, RPS7, RPS10, RPS15A, RPS17, RPS19, RPS20, RPS24, RPS26, RPS27, 
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RPS28, RPS29, RPS31, RPL5, RPL11, RPL15, RPL18, RPL26, RPL27, RPL35, 
RPL35A, TSR2, EPO), including those known to cause dyserythropoietic anemia. We 
next expanded our search to include all rare variants in these genes, and noted chrX: 
48,652,176 C>T in the fifth intron of GATA1 harbored by these two patients, but absent 
from ExAC and GnomAD.  The variant was hemizygous in both patients and carried in 
both mothers, suggesting a model of complete penetrance (the mother of Patient 1 was 
studied by exome sequencing, while the mother of Patient 2 had sequence analysis by 
Sanger sequencing).  All mutations were confirmed from genomic DNA samples of the 
patients or family members by Sanger sequencing. 
 
Minigene Assay and Splicing Analysis 
The GATA1 region flanking exon 5 and exon 6 was PCR amplified from genomic DNA 
from Patient 1 and from a healthy unrelated individual with the addition of XhoI and NotI 
restriction enzyme sites (Primers are the following: GATA1 intron 4: 
ATCATCCTCGAGTCTTGGGTCCTCCTGACATC; GATA1 intron 5: 
ATCATCGCGGCCGCCACATGGTCACACATTGCAG) for cloning into the 
pSpliceExpress vector (Addgene) (10). The constructs were transfected into human 
embryonic kidney (HEK) 293T cell (ATCC) with FuGENE (Promega). After reverse 
transcription of RNA obtained 48 hours post-transfection, RT-PCR was performed and 
amplified fragments were cloned using the TOPO TA Kit (Thermo Fisher) to enable 
confirmation of sequences through Sanger sequencing. For RT-PCR analyses, the 
segment of interest in GATA1 was amplified with the following primers (GATA1 Exon 5; 
AGTGGGGATCCCGTGTG and GATA1 Exon 6; ATCCTTCCGCATGGTCAGT). 
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Amplified products were linearized with 1X TBE-Urea (BioRad), incubated for 10 
minutes at 95°C, run on a 10% TBE-Urea Gel (BioRad), and subsequently visualized on 
a GelDoc instrument (BioRad) after 15 minutes of staining in ethidium bromide/ 1X TBE 
buffer. For semi-quantitative analyses, bands were quantified from scanned images using 
ImageJ software. 
 
Cell Culture and Lentiviral Transduction 
Human primary adult bone marrow derived CD34+ hematopoietic stem and progenitor 
cells (HSPCs) were obtained from Fred Hutchinson Cancer Research Institute and 
cultured as previously described (11, 12). The wild type or mutated (involving a 5 amino 
acid insertion corresponding with the observed intron retention event) GATA1 cDNA 
constructs were cloned into the HMD vector and transfected into 293T cells for lentiviral 
production, along with helper plasmids as described previously (11). The primary HSPCs 
undergoing erythroid differentiation were infected with lentiviruses on day 2 of 
differentiation. Multiple donors were used in different experiments, which all yielded 
similar results. On day 5 of differentiation, cells were sorted for GFP and maintained in 
culture for further terminal erythroid differentiation (13). Differentiating cells were 
collected on days 7, 9 and 12 for flow cytometric analysis with erythroid markers 
CD235a (HIR2), CD71 (OKT9), and CD49d (9F10) using an Accuri Instrument (BD 
Biosciences). G1E cells were kindly provided by the laboratory of Dr. Mitchell Weiss 
and cultured with 15% FBS, 1-thiogycerol, murine stem cell factor (SCF, Peprotech) and 
human erythropoietin (EPO, Amgen). G1E cells were infected with the lentiviruses 
discussed above and were either subjected to flow cytometric analysis with the mouse 
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erythroid marker Ter119 and GFP using an Accuri cytometer (BD Biosciences) or were 
sorted and subject to downstream analyses. Lentiviruses expressing SF3B1 wild type or 
K700E mutants, as described (14), were used to infect 293T cells one day prior to 
transfection, as above for the mini-gene assay. Cytocentrifugation was performed with 
approximately 100,000-200,000 cells using a Shandon Cytospin 4 on to polylysine-
coated slides at 300X RPM for 4 minutes. After drying, samples were stained with May-
Grünwald for 5 minutes then with Giemsa for 15 minutes, as previously described (15). 
 
RNA-seq Analysis 
Single-end RNA-seq datasets for five distinct maturation stages of primary human 
erythroid cells in biological triplicates were obtained from NCBI Gene Expression 
Omnibus (GEO; GSE53983) (16).  These datasets were aligned to the Ensembl GRCh37 
r75 genome and gene annotations using 2-Pass STAR alignment. Resultant alignments 
were imported into R. 
 
Analysis of MDS Patient Samples 
Cryopreserved bone marrow mononuclear cells from MDS patients with refractory 
anemia with ringed sideroblasts and healthy controls were thawed, washed, and 
recovered prior to staining with fluorescently-conjugated antibodies targeting CD235a 
(HIR2), CD71 (OKT9), and CD34 (4H11). Flow cytometric cell sorting for 
CD235a+CD71+ and CD34+ was performed using a FACSAria II Cell Sorter (BD 
Biosciences). Following sorting, the cells were washed and RNA was isolated using the 
Ambion small RNA extraction kit (Zymo). cDNA was synthesized from the recovered 
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RNA samples (20-40 ng) using the iScript cDNA Kit (BioRad). RT-PCR was carried out 
with with GATA1 primers and anormalization controls (primers GATA1 Exon 5: 
AGTGGGGATCCCGTGTG, GATA1 Exon 6: ATCCTTCCGCATGGTCAGT, GAPDH 
Exon 3: CACCAGGGCTGCTTTTAACT, and GAPDH Exon 4: 
GACAAGCTTCCCGTTCTCAG). Bands were visualized on denaturating gels and 
quantified as noted above. Samples were also analyzed with quantitative RT-PCR for 
GATA1 using a CFX96 Real Time Thermocycler (Biorad) with SYBR Green (BioRad) 
(primers GATA1 Exon 2: CCCCAGTTTGTGGATCCT and GATA1 Exon 3: 
CACAGTTGAGGCAGGGTAGAG, human ACTB Exon 3: 
AGAAAATCTGGCACCACACC, and human ACTB Exon 4: 
GGGGTGTTGAAGGTCTCAAA). 
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CHAPTER 4. CONCLUDING REMARKS & FUTURE DIRECTIONS 
 
4.1 Using genome editing to model disease: limitations and solutions 
The ease of genome sequencing has led to the discovery of genetic mutations 
causing a variety of human diseases. The wealth of data has now created a new primary 
challenge of understanding their functional and clinical significance. Genome editing 
emerged over the last several years as a promising approach to manipulate virtually any 
sequence in the genome with a high degree of target specificity. Multiple recent proof-of-
principle studies have described successful application of CRISPR/Cas9 to generate 
models of common diseases with well-established genetic alterations, such as lung cancer 
with CD74-ROS1 translocation and EML4-ALK and KIF5B-RET inversions (Choi and 
Meyerson 2014), acute myeloid leukemia with mutations in epigenetic modifiers, 
transcription factors, and cytokine signaling mediators (Heckl et al., 2014), colorectal 
cancer with mutations in defined tumor suppressor genes and oncogenes (Matano et al., 
2015), and Alzheimer’s disease with mutations in amyloid precursor protein (Paquet et 
al., 2016). However, no study to my awareness has modeled a novel disease with a novel 
mutation and provided insight into disease pathophysiology. 
Genome editing is the ideal approach to investigate a new disease-causing 
mutation because it can leave the rest of the genome unperturbed, preserving all known 
and unknown cis-acting regulatory elements and trans-acting factors in a cellular context 
that most resembles primary cells. The patients in our study presented with a distinct 
form of dyserythropoietic anemia characterized by persistence of fetal hemoglobin. 
Induction of fetal hemoglobin expression through childhood and beyond remains a topic 
of great interest because it can be harnessed for therapeutic purposes. A cellular model 
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that faithfully mimics the intronic mutation in its endogenous context provides 
opportunities to ask questions that exogenous expression studies are not well suited for. 
For example, how do global expression profiles and genome-wide occupancy sites of 
GATA1 differ between wild type and mutant cells and what can we extrapolate from them 
about fetal hemoglobin induction? The mutant GATA1 appears to be an inactive protein 
with no dominant negative activity, suggesting that the precise expression of functional 
GATA1 is critical to health and disease. As expression from an exogenous construct is 
difficult to control, replicating a mutation through genome editing remains the “gold 
standard” for elucidating a precise relationship between genotype and phenotype.    
In the course of creating a cellular model for the unusual dyserythropoietic 
anemia observed in our patients, I have discovered several key limitations of using 
genome editing to model a novel disease with a novel mutation. In the following sections, 
I will discuss these limitations and propose solutions:  
 
The disease-causing mutation impairs survival 
 When a mutation and its corresponding phenotype are not well characterized, the 
ability of a cellular or animal model to survive is an important assumption that warrants 
close examination. Here, I showed that editing of the target locus in GATA1 favors 
intronic sequences upstream from the Cas9 cleavage site and deletions of critical 
downstream sequences such as the canonical splice acceptor site and the last coding exon 
are exclusively observed in heterozygous clones. These results suggest that biallelic 
disruption of GATA1 predicted to alter translation and function may be selected against, 
as K562 cells may require a sufficient level of functional GATA1 for self-renewal. 
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Furthermore, isogenic cell lines that recapitulated the desired C>T intronic mutation in 
both alleles demonstrated concurrent deletions of the pathogenic alternative splice 
acceptor site (Mutants 1-2) or substitution of a nearby base (Mutant 3). It is possible that 
these additional modifications, which are upstream of the sgRNA PAM sequence not 
involved in Cas9-sgRNA binding, were found because they rescue K562 cells from the 
defect introduced by the intronic mutation. A more definitive experiment to show that 
K562 cells require GATA1 for survival would be to target the last exon for editing. 
CRISPR/Cas9 is particularly well suited for knockout studies because indels occur 
frequently with NHEJ and can cause frameshift mutations. In this study, I showed that it 
possible to generate nonspecific indels at the target locus with up to ~80% efficiency 
when the guide RNA is functionally validated and nucleofection parameters are 
optimized. Inability to detect homozygous frameshift mutations of any length would 
provide strong evidence that K562 cells cannot tolerate complete loss of GATA1 
function. This framework can be applied to future studies using genome editing to create 
a disease model when there is suspicion that the mutation jeopardizes survival. Prior to 
creating a disease model, one can target the gene for knockout via a validated guide 
RNA. If the cell or organism can survive without functional expression of the gene, then 
it is biologically feasible to create the disease model. However, if functional expression is 
required for survival, then an alternative approach such as generating patient-specific 
iPSCs from skin fibroblasts may be pursued. Differentiation of iPSCs can elucidate at 
which developmental stage the gene of interest becomes critical. Studies have described 
directed differentiation of iPSCs into red blood cells and a variety of other lineages (Dias 
et al. 2011; Wang et al., 2014; Dorn et al., 2015; Paquet et al., 2016; Pashos et al., 2017). 
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The mutation lacks nearby targeting sequences  
 Genome editing can alter any nucleotide in theory, but in practice it is constrained 
by specific sequence requirements. The use of CRISPR/Cas9, for example, depends on 
the presence of unique 20-nucleotide sequences with an adjacent PAM to minimize off-
target effects and enable Cas9 binding. The canonical PAM for S. pyogenes Cas9 is 
NGG, which occurs approximately every 8 bp in the human genome (Cong et al., 2013). 
In the 10 nucleotides flanking my mutation of interest, computational analysis identified 
only 1 suitable sgRNA targeting sequence. Kwart et al. (2017) measured mutation 
incorporation as a function of Cas9 cut-to-mutation distance and found that there is an 
exponential drop as distance increases. Homozygous mutation incorporation becomes 
inefficient (defined as <30% of clones with HDR) at a cut-to-mutation distance of >10 
bp. Of the 9 candidate sgRNAs I designed using the computational method, only one 
(sgRNA 5) was functional via transfection of 293T cells and surveyor nuclease assay. 
Unfortunately, it has a cut-to-mutation distance of 18 bp and the following experiments 
showed that the rate of mutation incorporation, even at overall editing efficiency of 
~80%, was only 3.8% (5 out of 133 clones). My study demonstrates that sequence 
constraint is a real limitation of genome editing with CRISPR/Cas9, especially for single 
nucleotide changes. One strategy to overcome this limitation is to use engineered Cas9 
nucleases with altered PAM specificities that have been validated in human cells and 
zebrafish (Kleinstiver et al., 2015). Alternatively, ZFNs and TALENs do not require 
PAM and can recognize target sequences of various lengths. Although assembling DNA 
binding domains is more challenging than synthesizing sgRNAs, many thousands of 
ZFNs and TALENs are already commercially available and validated (Gaj et al, 2013). 
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One study compared TALENs and CRISPR/Cas9 in targeting a single nucleotide 
mutation in HBB in !-thalassemia-derived iPSCs and found that TALENs mediated 
higher HDR and had fewer off-target events (Xu et al., 2015). 
  
Homology directed repair has low efficiency 
 HDR is required to create a precise mutation, insertion, or deletion. Classical 
homologous recombination is a difficult approach to targeted gene modification due to its 
low efficiency. Since the discovery that induction of a DSB increases the frequency of 
HDR by several orders of magnitude, targeted nucleases have played an indispensable 
role in HDR-mediated genome editing. HDR occurs much less frequently than NHEJ and 
is generally significant only in dividing cells (Saleh-Gohari and Helleday 2004). 
Furthermore, during HDR the full repair template is not always read, and whether a 
mutation is incorporated depends on its distance from the Cas9 cleavage site (Kwart et 
al., 2017). In this study, I increased the mass ratio of ssODN repair template to sgRNA to 
Cas9 from 2:2:1 to 10:3:1 to promote the likelihood of HDR. Among 133 clones, I 
observed 8 recombination events that incorporated the mutation (3 homozygous T/T 
clones and 2 heterozygous T/C clones). Pashos et al. (2017) recapitulated DNA variants 
associated with regulation of blood lipid traits in human pluripotent stem cells using 
CRISPR/Cas9 and also highlighted the low efficiency of HDR. For one variant, they 
obtained several heterozygous clones out of 140 but no homozygous clones. For another 
variant, they obtained a single heterozygous clone from 672 clones. For the third variant, 
they were not able to obtain any heterozygous or homozygous clones after screening a 
large number. In this case, they changed the repair template from ssODN to a targeting 
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vector with 500-bp homology arms and a puromycin resistance cassette and eventually 
isolated several homozygous clones. Recently, many groups have described even more 
effective strategies to optimize HDR. Lin et al. (2014) combined cell cycle 
synchronization using reversible chemical inhibitors with direct nucleofection of pre-
assembled Cas9 ribunucleoprotein and observed HDR rates up to 38%. Yang et al. (2016) 
arrested human pluripotent stem cells at the G2/M phase with anti-cancer agents ABT 
and nocodazole and observed a 6-fold increase in correct targeting cassette integration. 
Interestingly, concurrent inhibition of NHEJ with SCR7 did not further increase HDR, 
suggesting that HDR is the major repair mechanism following G2/M arrest. Richardson 
et al. (2016) rationally designed asymmetric ssODN repair template based on the DNA 
strand that Cas9 releases first and increased HDR rate up to 60%. Finally, Song and 
Stieger (2017) compared circular plasmid, linearized plasmid, and PCR products as the 
DNA repair template and observed highest HDR activity with linearized plasmid.  
 
Recurrent editing creates unwanted modifications 
 NHEJ occurs much more frequently than HDR during most of the cell cycle. I 
observed that the desired C>T mutation was often accompanied by deletion of the PAM 
and seed sequence of sgRNA 5 upstream of the canonical splice acceptor site. This result 
suggests that treasured clones that have incorporated the mutation via HDR may continue 
to undergo repeated editing until the targeting site of Cas9-sgRNA is sufficiently 
obliterated. Previously, I described a novel approach to isolate the desired mutation 
without additional modifications using two rounds of genome editing in a framework 
called CORRECT (Kwart et al., 2017). First, the desired mutation and a CRISPR/Cas-
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blocking mutation positioned in the PAM sequence (“re-Cas” method) or the 3’ seed 
sequence of the target sgRNA (“re-Guide” method) are created using a repair template 
containing both mutations. Then, the CRISPR/Cas-blocking mutation is removed using 
VRER-Cas9 (“re-Cas”), an engineered Cas9 that recognizes the previously altered PAM 
sequence, or a new sgRNA (“re-Guide”) that recognizes the previously altered 3’ seed 
sequence, with a “correct” repair template containing only the desired mutation. The team 
showed introducing pathogenic mutations with silent CRISPR/Cas-blocking mutations 
increased HDR accuracy dramatically. They then applied this approach to generate 
human iPSCs with mutations in amyloid precursor protein (APPSwe) and presenilin 1 
(PSEN1M146V) known to cause early onset Alzheimer’s disease (Paquet et al., 2016). They 
derived cortical neurons from edited iPSCs and observed genotype-dependent disease-
associated phenotype, such as increased total amyloid-! levels and increased ratio of the 
42-residue to 40-residue A! peptide. Mutant 3 in my study has the desired homozygous 
C>T mutation but developed a de novo homozygous C>A mutation 10 bp downstream, 
which is also 8 bp upstream from the Cas9 cleavage site and 2 bp upstream from the 
PAM sequence. If K562 cells can survive with the homozygous C>T mutation and no 
additional modifications, then this mutant would be an ideal candidate for further rounds 
of genome editing via CORRECT to reverse the C>A mutation, which is already <10 bp 
from the Cas9 cut site, an ideal distance for HDR.  
 
Guide RNA has off-target effects 
 The main strength of using genome editing to model disease is the ability to 
recapitulate mutations on an isogenic background and minimize potential confounders. 
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All 9 guide RNAs I designed for GATA1 editing had computed scores # 50 and were 
deemed high quality based on faithfulness of on-target activity. However, the estimated 
numbers of off-target sites ranged from 78 (sgRNA 5) to 478 (sgRNA 9) and raise the 
question of how often off-target genome editing occurs and whether observed phenotypic 
changes in a cellular model can truly be attributed to the mutation of interest. Recently, 
two groups developed in vitro biochemical methods for genome-wide assessment of 
CRISPR/Cas9 off-target sites. Tsai et al. (2017) used circularization to report cleavage 
effects in a technique called CIRCLE-seq. Genomic DNA is sheared and circularized, 
after which cleavage reactions are performed with Cas9 and in vitro transcribed sgRNA. 
Circular DNA molecules containing targeted sequences are linearized for adaptor 
ligation, PCR amplification, and high-throughput sequencing while unperturbed DNA 
remain circularized. Using genomic DNA from K562 cells, the authors identified 182 off-
target sites associated with an sgRNA targeting the human HBB gene. Cameron et al. 
(2017) used biotin ligation to report cleavage effects in another technique called SITE-
seq. Genomic DNA is digested with Cas9, after which cleaved DNA ends are tagged with 
biotin for subsequent enrichment and sequencing. Studies have described multiple 
strategies to minimize off-target effects. First, alteration of sgRNA including 3’ 
(tracrRNA) truncation, 5’ end shortening, and addition of GG to 5’ end can significantly 
improve target specificity and reduce off-target mutagenesis (Zhang et al, 2015). Second, 
decreasing the amount of sgRNA and Cas9 delivered can increase specificity but also 
lead to decreased on-target cleavage. Third, the D10 mutant nickase version of Cas9 
cleaves only one strand and can be with paired two sgRNAs, a strategy which can reduce 
off-target activity by 50-1,500 fold (Ran et al., 2013). Finally, catalytically inactive Cas9 
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fused to FokI nuclease domain (fCas9) has >140-fold higher target specificity than wild-
type Cas9 and at least 4-fold that of paired nickases (Guilinger et al., 2014; Tsai et al, 
2014). Since multiple clones are unlikely to have the same off-target effects, consistent 
phenotypic differences between multiple wild type and edited clones would argue for a 
true effect from the intended mutation. 
 
4.2 Alternative approaches can efficiently assess function of genetic variants  
 Recent progress has overcome many barriers to creating a faithful disease model. 
While genome editing remains an ideal approach to elucidate the genome-phenotype 
relationship by replicating mutations in their endogenous context and minimizing 
confounders, alternative approaches can efficiently assess function when generating a 
disease model requires substantial troubleshooting. With the advent of next-generation 
sequencing, many intronic or synonymous mutations that do not appear to alter protein 
coding have emerged as potential causes of human disease. These mutations likely reside 
in cis-acting elements that modulate pre-mRNA splicing.  
 Transient expression of minigene is a classical approach to characterize 
alternative splicing. As the primary elements regulating alternative splicing are typically 
located within 200-300 nucleotides of an exon and rarely beyond the upstream and the 
downstream exons, a “minigene” consisting of the genomic fragment of interest can be 
constructed in a plasmid vector and expressed exogenously to investigate splicing 
(Cooper 2005). RT-PCR enables quantification of mRNA including (or excluding) a 
variable region. Kishore et al. (2008) made the process even more efficient by developing 
a new vector called pSpliceExpress, which incorporates minigenes based on site-specific 
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recombination between bacteriophage lambda and E. coli chromosome, a process 
commercially popularized as Gateway cloning. Using this method, one can PCR amplify 
the genomic fragment containing the mutation of interest and flanking exons with 
attachment sites and directly insert it into pSpliceExpress by in vitro recombination. The 
vector contains 2 constitutive rat insulin exons flanking the insert for positive control and 
a ccdB element that is excised upon recombination, facilitating selection of bacteria 
transformed with plasmids containing the minigene. The authors report that generation of 
minigenes takes less than one week. In contrast, Kwart et al. (2017) estimates that 
generation of a scarless isogenic cell line with the mutation of interest using genome 
editing in the CORRECT framework takes approximately 3 months. The minigene assay 
has a few potential drawbacks: different cell lines may exhibit different splicing 
efficiencies and the same line may exhibit changes in splicing patterns over time. 
Encouragingly, my colleague Nour Abdulhay showed that altered GATA1 splicing due to 
activation of the alternative splice acceptor site is similarly observed in our patient 
samples, validating transient expression of minigene as an effective approach to studying 
mutations that regulate splicing. 
 Once aberrant gene expression is confirmed, alternative approaches to establish 
protein function include exogenous expression of mutated cDNA in cells and 
complementation in an animal model null for the gene of interest. With many tools 
ranging from traditional approaches to newest breakthroughs in genome editing, 
converting our wealth of data on the genetic basis of disease to functionally and clinically 
useful knowledge appears to be a matter of time.  
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